BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251-259. [PMID: 7640345 DOI: 10.1006/cyto.1995.0029] [Cited by in Crossref: 487] [Cited by in F6Publishing: 440] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Brookes MJ, Green JRB. Maintenance of Remission in Crohn???s Disease: Current and Emerging Therapeutic Options. Drugs 2004;64:1069-89. [DOI: 10.2165/00003495-200464100-00004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
2 Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious Adverse Events With Infliximab: Analysis of Spontaneously Reported Adverse Events. Clinical Gastroenterology and Hepatology 2007;5:729-735.e1. [DOI: 10.1016/j.cgh.2007.02.016] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 4.9] [Reference Citation Analysis]
3 Gileva IP, Ryazankin IA, Nepomnyashchikh TS, Totmenin AV, Maxutov ZA, Lebedev LR, Afinogenova GN, Pustoshilova NM, Shchelkunov SN. Expression of genes for orthopoxviral TNF-binding proteins in insect cells and investigation of the recombinant TNF-binding proteins. Mol Biol 2005;39:218-25. [DOI: 10.1007/s11008-005-0032-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
4 Pech T, Fujishiro J, Finger T, Ohsawa I, Praktiknjo M, von Websky M, Wehner S, Abu-Elmagd K, Kalff JC, Schaefer N. Perioperative infliximab application has marginal effects on ischemia-reperfusion injury in experimental small bowel transplantation in rats. Langenbecks Arch Surg. 2012;397:131-140. [PMID: 21960137 DOI: 10.1007/s00423-011-0853-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
5 van Wassenaer EA, Meester VL, Kindermann A, Koot BGP, Benninga MA, de Meij TGJ. Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients—a case-control study. Eur J Clin Pharmacol 2019;75:1445-50. [DOI: 10.1007/s00228-019-02715-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Ozeki T, Furuya Y, Nagano C, Matsui C, Takayanagi R, Yokoyama H, Yamada Y. Analysis of linkage between lymphotoxin alpha haplotype and polymorphisms in 5'-flanking region of tumor necrosis factor alpha gene associated with efficacy of infliximab for Crohn's disease patients. Mutat Res. 2006;602:170-174. [PMID: 17049565 DOI: 10.1016/j.mrfmmm.2006.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
7 Veerappan SG, O’Morain CA, Daly JS, Ryan BM. Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:1261-1272. [PMID: 21521250 DOI: 10.1111/j.1365-2036.2011.04667.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
8 Sedger LM, McDermott MF. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine Growth Factor Rev 2014;25:453-72. [PMID: 25169849 DOI: 10.1016/j.cytogfr.2014.07.016] [Cited by in Crossref: 422] [Cited by in F6Publishing: 390] [Article Influence: 52.8] [Reference Citation Analysis]
9 Aghdaei HA, Kadijani AA, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, Geraci M, Zali MR. An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients. United European Gastroenterol J. 2018;6:1074-1081. [PMID: 30228896 DOI: 10.1177/2050640618774637] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
10 Puar YR, Shanmugam MK, Fan L, Arfuso F, Sethi G, Tergaonkar V. Evidence for the Involvement of the Master Transcription Factor NF-κB in Cancer Initiation and Progression. Biomedicines 2018;6:E82. [PMID: 30060453 DOI: 10.3390/biomedicines6030082] [Cited by in Crossref: 97] [Cited by in F6Publishing: 92] [Article Influence: 24.3] [Reference Citation Analysis]
11 Bell SJ, Kamm MA. Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease. Aliment Pharmacol Ther. 2000;14:501-514. [PMID: 10792111 DOI: 10.1046/j.1365-2036.2000.00777.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.0] [Reference Citation Analysis]
12 Pathirana D, Ormerod A, Saiag P, Smith C, Spuls P, Nast A, Barker J, Bos J, Burmester G, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen S, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne J, Orzechowski H, Rantanen T, Reich K, Reytan N, Richards H, Thio H, van de Kerkhof P, Rzany B. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology 2009;23:1-70. [DOI: 10.1111/j.1468-3083.2009.03389.x] [Cited by in Crossref: 421] [Cited by in F6Publishing: 362] [Article Influence: 32.4] [Reference Citation Analysis]
13 Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J, Turino SY, Brodersen JB, Rashid S, Rasmussen BK, Avlund S, Olesen TB, Hoffmann HJ, Nexø BA, Sode J, Vogel U, Andersen V. Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy. Pharmacogenomics J 2018;18:87-97. [PMID: 28139755 DOI: 10.1038/tpj.2016.84] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
14 Murata Y, Onda A, Rydevik B, Takahashi K, Olmarker K. Selective Inhibition of Tumor Necrosis Factor-α Prevents Nucleus Pulposus-Induced Histologic Changes in the Dorsal Root Ganglion: . Spine 2004;29:2477-84. [DOI: 10.1097/01.brs.0000144406.17512.ea] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
15 Tallouzi MO, Barry RJ, Bucknall N, Mathers JM, Murray PI, Calvert MJ, Moore DJ, Denniston AK; Cochrane Eyes and Vision Group. Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012577] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
16 Slevin SM, Egan LJ. New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:2909-2920. [PMID: 26348448 DOI: 10.1097/mib.0000000000000533] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
17 Ehlers S. Tumor Necrosis Factor and Its Blockade in Granulomatous Infections: Differential Modes of Action of Infliximab and Etanercept? Clinical Infectious Diseases 2005;41:S199-203. [DOI: 10.1086/429998] [Cited by in Crossref: 142] [Cited by in F6Publishing: 116] [Article Influence: 8.4] [Reference Citation Analysis]
18 Richard-miceli C, Dougados M. Tumour Necrosis Factor-?? Blockers in Rheumatoid Arthritis: Review of the Clinical Experience. BioDrugs 2001;15:251-9. [DOI: 10.2165/00063030-200115040-00005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
19 Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608. [PMID: 12016425 DOI: 10.1053/gast.2002.33426] [Cited by in Crossref: 226] [Cited by in F6Publishing: 198] [Article Influence: 11.3] [Reference Citation Analysis]
20 Cornillie F, Shealy D, D’Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther. 2001;15:463-473. [PMID: 11284774 DOI: 10.1046/j.1365-2036.2001.00956.x] [Cited by in Crossref: 147] [Cited by in F6Publishing: 127] [Article Influence: 7.0] [Reference Citation Analysis]
21 Xu Z, Wang Q, Zhuang Y, Frederick B, Yan H, Bouman-Thio E, Marini JC, Keen M, Snead D, Davis HM, Zhou H. Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. J Clin Pharmacol 2010;50:276-84. [PMID: 19940229 DOI: 10.1177/0091270009340782] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 5.5] [Reference Citation Analysis]
22 Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Behçet's syndrome. J Neurol Sci 2008;272:99-105. [PMID: 18550081 DOI: 10.1016/j.jns.2008.05.002] [Cited by in Crossref: 77] [Cited by in F6Publishing: 55] [Article Influence: 5.5] [Reference Citation Analysis]
23 Gottlieb AB. Novel Immunotherapies for Psoriasis: Clinical Research Delivers New Hope for Patients and Scientific Advances. Journal of Investigative Dermatology Symposium Proceedings 2004;9:79-83. [DOI: 10.1111/j.1087-0024.2004.00831.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
24 Ehlers S. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis 2003;62 Suppl 2:ii37-42. [PMID: 14532147 DOI: 10.1136/ard.62.suppl_2.ii37] [Cited by in Crossref: 32] [Cited by in F6Publishing: 45] [Article Influence: 1.7] [Reference Citation Analysis]
25 Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev. 2010;15:543-562. [PMID: 20405319 DOI: 10.1007/s10741-010-9168-4] [Cited by in Crossref: 129] [Cited by in F6Publishing: 117] [Article Influence: 11.7] [Reference Citation Analysis]
26 Jay SM, Lee RT. Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair. Circ Res 2013;113:933-43. [PMID: 24030023 DOI: 10.1161/CIRCRESAHA.113.300215] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
27 Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal Infections Complicating Tumor Necrosis Factor α Blockade Therapy. Mayo Clinic Proceedings 2008;83:181-94. [DOI: 10.4065/83.2.181] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
28 Gottlieb AB. Clinical research helps elucidate the role of tumor necrosis factor-αin the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes. Lupus 2003;12:190-4. [DOI: 10.1191/0961203303lu354xx] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
29 Kierkus J, Szymanska E, Oracz G, Wiernicka A, Dadalski M. Profile of infliximab in the treatment of pediatric Crohn's disease. Pediatric Health Med Ther 2015;6:79-85. [PMID: 29388577 DOI: 10.2147/PHMT.S64943] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Makrygiannakis D, Catrina AI. Apoptosis as a mechanism of action of tumor necrosis factor antagonists in rheumatoid arthritis. J Rheumatol 2012;39:679-85. [PMID: 22422498 DOI: 10.3899/jrheum.110974] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
31 Maxwell JR, Potter C, Hyrich KL, Barton A, Worthington J, Isaacs JD, Morgan AW, Wilson AG; BRAGGSS. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Human Molecular Genetics 2008;17:3532-8. [DOI: 10.1093/hmg/ddn245] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 5.4] [Reference Citation Analysis]
32 Kramer N, Chuzhin Y, Kaufman LD, Ritter JM, Rosenstein ED. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis & Rheumatism 2002;47:670-1. [DOI: 10.1002/art.10803] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
33 Regueiro MD. Update in medical treatment of Crohn's disease. J Clin Gastroenterol 2000;31:282-91. [PMID: 11129268 DOI: 10.1097/00004836-200012000-00004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
34 Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Practice & Research Clinical Rheumatology 2004;18:59-80. [DOI: 10.1016/j.berh.2003.09.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
35 Mansouri B, Patel M, Menter A. Biological therapies for psoriasis. Expert Opin Biol Ther. 2013;13:1715-1730. [PMID: 24160990 DOI: 10.1517/14712598.2013.853739] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
36 Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biology of Blood and Marrow Transplantation 2004;10:655-68. [DOI: 10.1016/j.bbmt.2004.07.007] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
37 Giles JT, Bathon JM. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004;19:320-34. [PMID: 15523118 DOI: 10.1177/0885066604267854] [Cited by in Crossref: 81] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
38 El-shabrawi Y, Hermann J. Anti–tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen b27–associated acute anterior uveitis. Ophthalmology 2002;109:2342-6. [DOI: 10.1016/s0161-6420(02)01292-7] [Cited by in Crossref: 96] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
39 de Baey A, Mende I, Baretton G, Greiner A, Hartl WH, Baeuerle PA, Diepolder HM. A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha. J Immunol 2003;170:5089-94. [PMID: 12734354 DOI: 10.4049/jimmunol.170.10.5089] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 3.3] [Reference Citation Analysis]
40 Buch MH. Sequential use of biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2010;22:321-9. [PMID: 20190641 DOI: 10.1097/BOR.0b013e328337bd01] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
41 Park JW, Smolen J. Monoclonal antibody therapy. Drug Discovery and Design. Elsevier; 2001. pp. 369-421. [DOI: 10.1016/s0065-3233(01)56010-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
42 Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, Vafa O, Gunn G, Tam S, Sague S. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs. 2010;2:428-439. [PMID: 20519961 DOI: 10.4161/mabs.12304] [Cited by in Crossref: 153] [Cited by in F6Publishing: 131] [Article Influence: 12.8] [Reference Citation Analysis]
43 Shukla R, Vender RB. Pharmacology of TNF inhibitors. In: Weinberg JM, Buchholz R, editors. TNF-alpha Inhibitors. Basel: Birkhäuser-Verlag; 2006. pp. 23-44. [DOI: 10.1007/3-7643-7438-1_3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Augustsson J, Jonsdottir T, Klareskog L, van Vollenhoven RF. Infliximab in the treatment of rheumatoid arthritis. Aging Health 2006;2:19-33. [DOI: 10.2217/1745509x.2.1.19] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
45 Fausel R, Afzali A. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag 2015;11:63-73. [PMID: 25609972 DOI: 10.2147/TCRM.S55506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
46 Laroui H, Viennois E, Xiao B, Canup BS, Geem D, Denning TL, Merlin D. Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. J Control Release 2014;186:41-53. [PMID: 24810114 DOI: 10.1016/j.jconrel.2014.04.046] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 10.6] [Reference Citation Analysis]
47 Navarra SV, Tang B, Lu L, Lin HY, Mok CC, Asavatanabodee P, Suwannalai P, Hussein H, Rahman MU. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia. Int J Rheum Dis 2014;17:291-8. [PMID: 24131578 DOI: 10.1111/1756-185X.12188] [Cited by in Crossref: 41] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
48 Kleyn CE, Griffiths CE. Infliximab for the treatment of psoriasis. Expert Opin Biol Ther 2006;6:797-805. [PMID: 16856801 DOI: 10.1517/14712598.6.8.797] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
49 Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, Pérez-Pariente JM, López-Vázquez A, de Francisco R, Rodrigo L. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn’s disease. Am J Gastroenterol. 2002;97:2350-2356. [PMID: 12358255 DOI: 10.1111/j.1572-0241.2002.05990.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 22] [Article Influence: 0.5] [Reference Citation Analysis]
50 Ranganathan P. Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics 2005;6:481-90. [DOI: 10.2217/14622416.6.5.481] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
51 Pech T, von Websky M, Ohsawa I, Kitamura K, Praktiknjo M, Jafari A, Vilz TO, Wehner S, Abu-elmagd K, Kalff JC, Schaefer N. Intestinal Regeneration, Residual Function and Immunological Priming Following Rescue Therapy After Rat Small Bowel Transplantation: Regeneration After Intestinal Transplantation. American Journal of Transplantation 2012;12:S9-S17. [DOI: 10.1111/j.1600-6143.2012.04262.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
52 Stio M, Martinesi M, Bruni S, Treves C, d'Albasio G, Bagnoli S, Bonanomi AG. Interaction among vitamin D(3) analogue KH 1060, TNF-alpha, and vitamin D receptor protein in peripheral blood mononuclear cells of inflammatory bowel disease patients. Int Immunopharmacol. 2006;6:1083-1092. [PMID: 16714211 DOI: 10.1016/j.intimp.2006.01.018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
53 Carter JD, Valeriano J, Vasey FB, Bognar B. Refractory neurosarcoidosis: A dramatic response to infliximab. The American Journal of Medicine 2004;117:277-9. [DOI: 10.1016/j.amjmed.2004.03.013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
54 Jang YW, Park YS, Kim SH, Jo YJ, Jo YK, Ahn SB, Seo YS, Hong YO. A Case of Crohn's Disease Having Normal Delivery after Infliximab Treatment during Early Pregnancy. Korean J Gastroenterol 2013;61:37. [DOI: 10.4166/kjg.2013.61.1.37] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Chaudhari U, Romano P, Mulcahy L, Dooley L, Baker D, Gottlieb A. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. The Lancet 2001;357:1842-7. [DOI: 10.1016/s0140-6736(00)04954-0] [Cited by in Crossref: 651] [Cited by in F6Publishing: 122] [Article Influence: 31.0] [Reference Citation Analysis]
56 Hedrich O, Finley J, Konstam MA, Udelson JE. Novel neurohormonal antagonist strategies: vasopressin antagonism, anticytokine therapy, and endothelin antagonism in patients who have heart failure. Heart Fail Clin 2005;1:103-27. [PMID: 17386838 DOI: 10.1016/j.hfc.2004.12.002] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
57 Luk JM, Wong K. MONOCLONAL ANTIBODIES AS TARGETING AND THERAPEUTIC AGENTS: PROSPECTS FOR LIVER TRANSPLANTATION, HEPATITIS AND HEPATOCELLULAR CARCINOMA. Clin Exp Pharmacol Physiol 2006;33:482-8. [DOI: 10.1111/j.1440-1681.2006.04396.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
58 Lamireau T, Cézard J, Dabadie A, Goulet O, Lachaux A, Turck D, Maurage C, Morali A, Sokal E, Belli D, Stoller J, Cadranel S, Ginies J, Viola S, Huet F, Languepin J, Lenaerts C, Bury F, Sarles J. Efficacy and Tolerance of Infliximab in Children and Adolescents with Crohn’s Disease: . Inflammatory Bowel Diseases 2004;10:745-50. [DOI: 10.1097/00054725-200411000-00008] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
59 Denmark VK, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Review of Clinical Immunology 2014;9:77-92. [DOI: 10.1586/eci.12.91] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
60 van Deventer SJ. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology. 2001;121:1242-1246. [PMID: 11677219 DOI: 10.1053/gast.2001.29035] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 4.0] [Reference Citation Analysis]
61 Rider P, Carmi Y, Cohen I. Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations. Int J Cell Biol 2016;2016:9259646. [PMID: 28083070 DOI: 10.1155/2016/9259646] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 15.8] [Reference Citation Analysis]
62 Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol 2003;21:392-7. [PMID: 14678719 DOI: 10.1016/j.clindermatol.2003.08.015] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 3.6] [Reference Citation Analysis]
63 Sands BE. Novel therapies for inflammatory bowel disease. Gastroenterol Clin North Am 1999;28:323-51. [PMID: 10372271 DOI: 10.1016/s0889-8553(05)70059-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
64 Barry RJ, Tallouzi MO, Bucknall N, Mathers JM, Murray PI, Calvert MJ, Moore DJ, Denniston AK. Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis. Cochrane Database Syst Rev 2018;12:CD012577. [PMID: 30562409 DOI: 10.1002/14651858.CD012577.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
65 Wu M, Sun J, Wu D, Xu J, Wei J, Wang Z, Yu J, Li S, Zhang H, Ding Y. A Phase I, Randomized, Double-Blind, Single-Dose, Parallel-Group Study to compare Pharmacokinetic Similarity, Safety, and Immunogenicity Between BAT2506 and Golimumab in Healthy Chinese Male Subjects. Expert Opin Investig Drugs 2021;30:77-83. [PMID: 33241960 DOI: 10.1080/13543784.2021.1851364] [Reference Citation Analysis]
66 Kapadia MK, Rubin PAD. The Emerging Use of TNF-?? Inhibitors in Orbital Inflammatory Disease: . International Ophthalmology Clinics 2006;46:165-81. [DOI: 10.1097/00004397-200604620-00014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
67 Sondermann P, Szymkowski DE. Harnessing Fc receptor biology in the design of therapeutic antibodies. Current Opinion in Immunology 2016;40:78-87. [DOI: 10.1016/j.coi.2016.03.005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 7.7] [Reference Citation Analysis]
68 Liao H, Zhong Z, Liu Z, Zou X. Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. Int J Rheum Dis 2017;20:161-8. [DOI: 10.1111/1756-185x.12970] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 3.4] [Reference Citation Analysis]
69 Takazoe M, Tanaka T, Kondo K, Ichimori T, Shinoda T. The Present Status and the Recent Development of the Treatment for Inflammatory Bowel Diseases: Desirable Effect of Extracorporeal Immunomodulation. Therapher Dial 2002;6:305-11. [DOI: 10.1046/j.1526-0968.2002.00445.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
70 Zidi I, Mestiri S, Bartegi A, Amor NB. TNF-alpha and its inhibitors in cancer. Med Oncol. 2010;27:185-198. [PMID: 19277912 DOI: 10.1007/s12032-009-9190-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
71 Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology. 2000;119:1148-1157. [PMID: 11040201 DOI: 10.1053/gast.2000.18160] [Cited by in Crossref: 245] [Cited by in F6Publishing: 236] [Article Influence: 11.1] [Reference Citation Analysis]
72 Poggioli G, Laureti S, Campieri M, Pierangeli F, Gionchetti P, Ugolini F, Gentilini L, Bazzi P, Rizzello F, Coscia M. Infliximab in the treatment of Crohn's disease. Ther Clin Risk Manag 2007;3:301-8. [PMID: 18360638 DOI: 10.2147/tcrm.2007.3.2.301] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
73 Louis EJ, Watier HE, Schreiber S, Hampe J, Taillard F, Olson A, Thorne N, Zhang H, Colombel JF. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics. 2006;16:911-914. [PMID: 17108815 DOI: 10.1097/01.fpc.0000230421.12844.fd] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 4.1] [Reference Citation Analysis]
74 Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244-279. [PMID: 18155297 DOI: 10.1016/j.pharmthera.2007.10.001] [Cited by in Crossref: 989] [Cited by in F6Publishing: 900] [Article Influence: 65.9] [Reference Citation Analysis]
75 Pearce DJ, Feldman SR. Update on infliximab: an intravenous biologic therapy for psoriasis. Expert Review of Dermatology 2014;2:707-13. [DOI: 10.1586/17469872.2.6.707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T, Mirkov MU, Canhao H, Ikari K, Terao C, Okada Y, Wedrén S, Askling J, Yamanaka H, Momohara S, Taniguchi A, Ohmura K, Matsuda F, Mimori T, Gupta N, Kuchroo M, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, Herenius M, Doorenspleet ME, Tak PP, Crusius JB, van der Horst-Bruinsma IE, Wolbink GJ, van Riel PL, van de Laar M, Guchelaar HJ, Shadick NA, Allaart CF, Huizinga TW, Toes RE, Kimberly RP, Bridges SL Jr, Criswell LA, Moreland LW, Fonseca JE, de Vries N, Stranger BE, De Jager PL, Raychaudhuri S, Weinblatt ME, Gregersen PK, Mariette X, Barton A, Padyukov L, Coenen MJ, Karlson EW, Plenge RM. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet 2013;9:e1003394. [PMID: 23555300 DOI: 10.1371/journal.pgen.1003394] [Cited by in Crossref: 115] [Cited by in F6Publishing: 99] [Article Influence: 12.8] [Reference Citation Analysis]
77 Levy-clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert Panel Recommendations for the Use of Anti–Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders. Ophthalmology 2014;121:785-796.e3. [DOI: 10.1016/j.ophtha.2013.09.048] [Cited by in Crossref: 268] [Cited by in F6Publishing: 207] [Article Influence: 33.5] [Reference Citation Analysis]
78 Travassos WJ, Cheifetz AS. Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005;8:187-196. [PMID: 15913508 DOI: 10.1007/s11938-005-0011-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
79 Mutlu GM, Mutlu EA, Bellmeyer A, Rubinstein I. Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy. Am J Med 2006;119:639-46. [PMID: 16887405 DOI: 10.1016/j.amjmed.2006.01.015] [Cited by in Crossref: 46] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
80 Chen A, Truong AK, Worswick S. The role of biologics in the treatment of chronic granuloma annulare. Int J Dermatol 2018;58:622-6. [DOI: 10.1111/ijd.14350] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
81 Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol. 2003;49:S112-S117. [PMID: 12894134 DOI: 10.1016/s0190-9622(03)01143-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
82 Lee YH, Woo JH, Rho YH, Choi SJ, Ji JD, Song GG. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int 2008;28:553-9. [DOI: 10.1007/s00296-007-0475-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
83 Hanauer SB, Cohen RD, Becker RV, Larson LR, Vreeland MG. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clinical Therapeutics 1998;20:1009-28. [DOI: 10.1016/s0149-2918(98)80082-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
84 Buch MH, Emery P. Nonresponse to tumor necrosis factor antagonists—is there any point in re-treatment? Nat Rev Rheumatol 2006;2:288-9. [DOI: 10.1038/ncprheum0210] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
85 Holtmann MH, Neurath MF. Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis. 2005;20:1-8. [PMID: 15459771 DOI: 10.1007/s00384-004-0634-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
86 Armstrong AM, Gardiner KR, Kirk SJ, Halliday MI, Rowlands BJ. Tumour necrosis factor and inflammatory bowel disease: TUMOUR NECROSIS FACTOR AND INFLAMMATORY BOWEL DISEASE. Br J Surg 1997;84:1051-8. [DOI: 10.1046/j.1365-2168.1997.02860.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Gupta AK, Skinner AR. A Review of the Use of Infliximab to Manage Cutaneous Dermatoses. J Cutan Med Surg 2004;8:77-89. [DOI: 10.1177/120347540400800202] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
88 Mizuochi Y, Okajima K, Harada N, Molor-erdene P, Uchiba M, Komura H, Tsuda T, Katsuya H. Carvedilol, a nonselective β-blocker, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. Translational Research 2007;149:223-30. [DOI: 10.1016/j.trsl.2006.11.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
89 Rongioletti F, Borenstein M, Kirsner R, Kerdel F. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatolog Treat 2003;14:222-5. [PMID: 14660268 DOI: 10.1080/09546630310010895] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
90 Malviya G, Salemi S, Laganà B, Diamanti AP, D'Amelio R, Signore A. Biological therapies for rheumatoid arthritis: progress to date. BioDrugs 2013;27:329-45. [PMID: 23558378 DOI: 10.1007/s40259-013-0021-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
91 Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002;41:449-52. [DOI: 10.1046/j.1365-4362.2002.01543.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
92 Bargagli E, Olivieri C, Rottoli P. Cytokine modulators in the treatment of sarcoidosis. Rheumatol Int 2011;31:1539-44. [PMID: 21644041 DOI: 10.1007/s00296-011-1969-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
93 Kim JY, Park JN, Lee JG, Lee YA, Kim YH, Hong SJ, Yang HI, Lee SH. The use of etanercept in a patient with disseminated tuberculosis. Rheumatol Int 2009;29:1377-80. [PMID: 19151979 DOI: 10.1007/s00296-008-0836-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
94 Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother. 2003;37:1256-1265. [PMID: 12921510 DOI: 10.1345/aph.1C039] [Cited by in Crossref: 59] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
95 Dekkers PE, Lauw FN, ten Hove T, te Velde AA, Lumley P, Becherer D, van Deventer SJ, van der Poll T. The Effect of a Metalloproteinase Inhibitor (GI5402) on Tumor Necrosis Factor- (TNF-) and TNF- Receptors During Human Endotoxemia. Blood 1999;94:2252-8. [DOI: 10.1182/blood.v94.7.2252.419k25_2252_2258] [Cited by in Crossref: 37] [Article Influence: 1.6] [Reference Citation Analysis]
96 Feldman M, Taylor P, Paleolog E, Brennan FM, Maini RN. Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Transplant Proc 1998;30:4126-7. [PMID: 9865320 DOI: 10.1016/s0041-1345(98)01365-7] [Cited by in Crossref: 71] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
97 Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261-1265. [PMID: 15127338 DOI: 10.1086/383317] [Cited by in Crossref: 665] [Cited by in F6Publishing: 545] [Article Influence: 36.9] [Reference Citation Analysis]
98 Blam ME, Stein RB, Lichtenstein GR. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol 2001;96:1977-97. [PMID: 11467623 DOI: 10.1111/j.1572-0241.2001.03931.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 36] [Article Influence: 0.7] [Reference Citation Analysis]
99 Khanna D, Mcmahon M, Furst DE. Anti-tumor necrosis factor ? therapy and heart failure: What have we learned and where do we go from here? Arthritis & Rheumatism 2004;50:1040-50. [DOI: 10.1002/art.20164] [Cited by in Crossref: 72] [Cited by in F6Publishing: 59] [Article Influence: 4.0] [Reference Citation Analysis]
100 Lamoureux F, Picarda G, Rousseau J, Gourden C, Battaglia S, Charrier C, Pitard B, Heymann D, Rédini F. Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. Mol Cancer Ther 2008;7:3389-98. [PMID: 18852142 DOI: 10.1158/1535-7163.MCT-08-0497] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
101 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
102 Friedrich EE, Washburn NR. Transport patterns of anti-TNF-α in burn wounds: Therapeutic implications of hyaluronic acid conjugation. Biomaterials 2017;114:10-22. [PMID: 27837681 DOI: 10.1016/j.biomaterials.2016.11.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
103 Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 1997;40:470-4. [PMID: 9176073 DOI: 10.1136/gut.40.4.470] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 2.4] [Reference Citation Analysis]
104 Colagiovanni DB, Suniga MA, Frazier JL, Edwards CK, Fleshner M, Mccay JA, White KL, Shopp GM. TNF-α Blockade by a Dimeric TNF Type I Receptor Molecule Selectively Inhibits Adaptive Immune Responses. Immunopharmacology and Immunotoxicology 2008;22:627-51. [DOI: 10.3109/08923970009016429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
105 El-Menyar AA. Cytokines and myocardial dysfunction: state of the art. J Card Fail 2008;14:61-74. [PMID: 18226775 DOI: 10.1016/j.cardfail.2007.09.006] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 5.1] [Reference Citation Analysis]
106 Rudwaleit M, Sieper J. Infliximab for the treatment of ankylosing spondylitis. Expert Opin Biol Ther 2005;5:1095-109. [PMID: 16050786 DOI: 10.1517/14712598.5.8.1095] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
107 Brynskov J, Foegh P, Pedersen G, Ellervik C, Kirkegaard T, Bingham A, Saermark T. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002;51:37-43. [PMID: 12077089 DOI: 10.1136/gut.51.1.37] [Cited by in Crossref: 131] [Cited by in F6Publishing: 132] [Article Influence: 6.6] [Reference Citation Analysis]
108 Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology. 2001;120:995-999. [PMID: 11231954 DOI: 10.1053/gast.2001.22556] [Cited by in Crossref: 112] [Cited by in F6Publishing: 90] [Article Influence: 5.3] [Reference Citation Analysis]
109 Astrakhantseva IV, Efimov GA, Drutskaya MS, Kruglov AA, Nedospasov SA. Modern anti-cytokine therapy of autoimmune diseases. Biochemistry (Mosc) 2014;79:1308-21. [PMID: 25716724 DOI: 10.1134/S0006297914120049] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
110 Miehsler W, Reinisch W, Kazemi-shirazi L, Dejaco C, Novacek G, Ferenci P, Herbst F, Karner J, Téleky B, Schober E, Vogelsang H. Infliximab: Lack of Efficacy on Perforating Complications in Crohn's Disease. Inflammatory Bowel Diseases 2004;10:36-40. [DOI: 10.1097/00054725-200401000-00006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
111 Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005;21:251-258. [PMID: 15691299 DOI: 10.1111/j.1365-2036.2005.02309.x] [Cited by in Crossref: 152] [Cited by in F6Publishing: 145] [Article Influence: 8.9] [Reference Citation Analysis]
112 Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacology & Therapeutics 2008;117:244-79. [DOI: 10.1016/j.pharmthera.2007.10.001] [78495111110.1016/j.pharmthera.2007.10.001','', '1007-9327')">Reference Citation Analysis]
113 Kuffler DP. Injury-Induced Effectors of Neuropathic Pain. Mol Neurobiol 2020;57:51-66. [PMID: 31701439 DOI: 10.1007/s12035-019-01756-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Tam SH, McCarthy SG, Armstrong AA, Somani S, Wu SJ, Liu X, Gervais A, Ernst R, Saro D, Decker R, Luo J, Gilliland GL, Chiu ML, Scallon BJ. Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality. Antibodies (Basel) 2017;6:E12. [PMID: 31548527 DOI: 10.3390/antib6030012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
115 Couriel DR, Hicks K, Giralt S, Champlin RE. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation: . Current Opinion in Oncology 2000;12:582-7. [DOI: 10.1097/00001622-200011000-00011] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 2.4] [Reference Citation Analysis]
116 Faria AP, Ritter AMV, Santa-Catharina A, Souza DP, Naseri EP, Bertolo MB, Pioli MR, Carvalho CC, Modolo R, Moreno H. Effects of Anti-TNF alpha Therapy on Blood Pressure in Resistant Hypertensive Subjects: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Arq Bras Cardiol 2021;116:443-51. [PMID: 33909773 DOI: 10.36660/abc.202190703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Dhillon S, Loftus EV. Medical Therapy of Crohn's Disease. Curr Treat Options Gastroenterol 2005;8:19-30. [PMID: 15625031 DOI: 10.1007/s11938-005-0048-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
118 Li LY, Brimhall AK, Menter A. Systemic therapy for moderate-to-severe psoriasis. Expert Review of Dermatology 2014;1:77-92. [DOI: 10.1586/17469872.1.1.77] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
119 Kolho KL, Ruuska T, Savilahti E. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr. 2007;96:128-130. [PMID: 17187619 DOI: 10.1111/j.1651-2227.2007.00042.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
120 Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Emery P, Reece R, Quinn M. Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanercept. Arthritis Rheum 2007;57:448-53. [DOI: 10.1002/art.22617] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
121 Rao K, Rao A, Karlsson H, Jagani M, Veys P, Amrolia PJ. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease. J Pediatr Hematol Oncol 2009;31:456-61. [PMID: 19648797 DOI: 10.1097/MPH.0b013e31819daf60] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
122 Rosa FGD, Shaz D, Campagna AC, Dellaripa PF, Khettry U, Craven DE. Invasive Pulmonary Aspergillosis Soon After Therapy With Infliximab, a Tumor Necrosis Factor-Alpha–Neutralizing Antibody: A Possible Healthcare-Associated Case? Infect Control Hosp Epidemiol 2003;24:477-82. [DOI: 10.1086/502250] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 9.9] [Reference Citation Analysis]
123 Li J, Gong YM, Wu J, Wu WJ, Cai W. Anti-tumor necrosis factor-α monoclonal antibody alleviates parenteral nutrition-associated liver disease in mice. JPEN J Parenter Enteral Nutr 2012;36:219-25. [PMID: 22275328 DOI: 10.1177/0148607111424412] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
124 D'haens G. The impact of anti-TNF (Infliximab or RemicadeR) on the surgical management of Crohn's disease. Colorect Dis 2001;3:7-10. [DOI: 10.1046/j.1463-1318.2001.003s2007.x] [Reference Citation Analysis]
125 Probert CS, Hearing SD, Schreiber S, Kühbacher T, Ghosh S, Arnott ID, Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998-1002. [PMID: 12801957 DOI: 10.1136/gut.52.7.998] [Cited by in Crossref: 233] [Cited by in F6Publishing: 224] [Article Influence: 12.3] [Reference Citation Analysis]
126 Erickson AR, Mikuls TR. Switching anti-TNF-α agents: What is the evidence? Curr Rheumatol Rep 2007;9:416-20. [DOI: 10.1007/s11926-007-0066-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
127 Gazouli M, Anagnostopoulos AK, Papadopoulou A, Vaiopoulou A, Papamichael K, Mantzaris G, Theodoropoulos GE, Anagnou NP, Tsangaris GT. Serum protein profile of Crohn's disease treated with infliximab. J Crohns Colitis. 2013;7:e461-e470. [PMID: 23562004 DOI: 10.1016/j.crohns.2013.02.021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
128 Ware CF. Protein therapeutics targeted at the TNF superfamily. Adv Pharmacol 2013;66:51-80. [PMID: 23433455 DOI: 10.1016/B978-0-12-404717-4.00002-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
129 Nagayoshi R, Nagai T, Matsushita K, Sato K, Sunahara N, Matsuda T, Nakamura T, Komiya S, Onda M, Matsuyama T. Effectiveness of anti-folate receptor β antibody conjugated with truncatedPseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages. Arthritis Rheum 2005;52:2666-75. [DOI: 10.1002/art.21228] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
130 van Montfrans C, Camoglio L, van Deventer SJ. Immunotherapy of Crohn's disease. Mediators Inflamm 1998;7:149-52. [PMID: 9705600 DOI: 10.1080/09629359891063] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
131 Su C, Lichtenstein GR. Are there predictors of Remicade treatment success or failure? Adv Drug Deliv Rev. 2005;57:237-245. [PMID: 15555740 DOI: 10.1016/j.addr.2004.08.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
132 Kruglov AA, Nedospasov SA. Comment on "experimental arthritis triggers periodontal disease in mice: involvement of TNF-α and the oral microbiota". J Immunol 2012;188:4-5; author reply 5-6. [PMID: 22187480 DOI: 10.4049/jimmunol.1190080] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
133 Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004;104:649-54. [PMID: 15069017 DOI: 10.1182/blood-2003-12-4241] [Cited by in Crossref: 215] [Cited by in F6Publishing: 180] [Article Influence: 11.9] [Reference Citation Analysis]
134 Sofia MA, Rubin DT. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. Dig Dis Sci 2017;62:833-42. [PMID: 28197743 DOI: 10.1007/s10620-017-4479-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
135 Montes A, Perez-Pampin E, Narváez J, Cañete JD, Navarro-Sarabia F, Moreira V, Fernández-Nebro A, Del Carmen Ordóñez M, de la Serna AR, Magallares B, Vasilopoulos Y, Sarafidou T, Caliz R, Ferrer MA, Joven B, Carreira P, Gómez-Reino JJ, Gonzalez A. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenet Genomics 2014;24:238-45. [PMID: 24667440 DOI: 10.1097/FPC.0000000000000042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
136 Dick AD, Duncan L, Hale G, Waldmann H, Isaacs J. Neutralizing TNF-alpha Activity Modulates T-cell Phenotype and Function in Experimental Autoimmune Uveoretinitis. Journal of Autoimmunity 1998;11:255-64. [DOI: 10.1006/jaut.1998.0197] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 2.8] [Reference Citation Analysis]
137 Stenger S. Immunological control of tuberculosis: role of tumour necrosis factor and more. Ann Rheum Dis 2005;64 Suppl 4:iv24-8. [PMID: 16239381 DOI: 10.1136/ard.2005.042531] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 3.4] [Reference Citation Analysis]
138 Kimura K, Takayanagi R, Yokoyama H, Yamada Y. Theory-based analysis of anti-inflammatory effect of infliximab on Crohn's disease and rheumatoid arthritis. Rheumatol Int 2012;32:145-50. [PMID: 20680285 DOI: 10.1007/s00296-010-1553-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
139 Saraceno R, Faleri S, Ruzzetti M, Centonze D, Chimenti S. Prevalence and management of panic attacks during infliximab infusion in psoriatic patients. Dermatology 2012;225:236-41. [PMID: 23183380 DOI: 10.1159/000343609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
140 Nagajothi N, Matsui WH, Mukhina GL, Brodsky RA. Enhanced cytotoxicity of rituximab following genetic and biochemical disruption of glycosylphosphatidylinositol anchored proteins. Leuk Lymphoma 2004;45:795-9. [PMID: 15160958 DOI: 10.1080/10428190310001625700] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
141 de Angelis R, Gasparini S, Bugatti L, Filosa G. Early Videocapillaroscopic Changes of the Psoriatic Skin after Anti-Tumour Necrosis Factor Alpha Treatment. Dermatology 2005;210:241-3. [DOI: 10.1159/000083519] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
142 Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum. 2003;48:2155-2162. [PMID: 12905468 DOI: 10.1002/art.11098] [Cited by in Crossref: 144] [Cited by in F6Publishing: 149] [Article Influence: 7.6] [Reference Citation Analysis]
143 Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK. Alterations in the function of circulating mononuclear cells derived from patients with Crohn’s disease treated with mastic. World J Gastroenterol 2007; 13(45): 6031-6036 [DOI: 10.3748/wjg.v13.i45.6031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
144 Hare NC, Arnott ID, Satsangi J. Therapeutic options in acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;2:357-70. [DOI: 10.1586/17474124.2.3.357] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
145 Richter JA, Bickston SJ. Infliximab use in luminal Crohn's disease. Gastroenterol Clin North Am 2006;35:775-93. [PMID: 17129813 DOI: 10.1016/j.gtc.2006.09.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
146 Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20 Suppl 2:1-9. [PMID: 15335408 DOI: 10.1111/j.1365-2036.2004.02058.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
147 Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002;91:988-98. [PMID: 12456484 DOI: 10.1161/01.res.0000043825.01705.1b] [Cited by in Crossref: 673] [Cited by in F6Publishing: 253] [Article Influence: 33.7] [Reference Citation Analysis]
148 Bellizzi A, Barucca V, Fioriti D, Colosimo MT, Mischitelli M, Anzivino E, Chiarini F, Pietropaolo V. Early years of biological agents therapy in Crohn's disease and risk of the human polyomavirus JC reactivation. J Cell Physiol 2010;224:316-26. [DOI: 10.1002/jcp.22146] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
149 Ovejero-benito MC, Prieto-pérez R, Llamas-velasco M, Muñoz-aceituno E, Reolid A, Saiz-rodríguez M, Belmonte C, Román M, Ochoa D, Talegón M, Cabaleiro T, Daudén E, Abad-santos F. Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis. Pharmacogenomics 2018;19:7-16. [DOI: 10.2217/pgs-2017-0143] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
150 Papaconstantinou I, Zeglinas C, Gazouli M, Nastos K, Yiallourou A, Lykoudis P, Evangelou K, Papalois A, Papaioannou M, Vlachogiannakos J, Tzathas C. Effect of infliximab on the healing of intestinal anastomosis. An experimental study in rats. International Journal of Surgery 2014;12:969-75. [DOI: 10.1016/j.ijsu.2014.07.271] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
151 Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muià C, Esposito E, Bramanti P, Cuzzocrea S. TNF-α BLOCKAGE IN A MOUSE MODEL OF SCI: EVIDENCE FOR IMPROVED OUTCOME. Shock 2008;29:32-41. [DOI: 10.1097/shk.0b013e318059053a] [Cited by in Crossref: 23] [Cited by in F6Publishing: 46] [Article Influence: 1.6] [Reference Citation Analysis]
152 Comerford LW, Bickston SJ. Treatment of luminal and fistulizing Crohn's disease with infliximab. Gastroenterol Clin North Am. 2004;33:387-406, xi. [PMID: 15177545 DOI: 10.1016/j.gtc.2004.02.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
153 Rojas-villarraga A, Agudelo CA, Pineda-tamayo R, Porras A, Matute G, Anaya JM. Tuberculosis en pacientes tratados con antagonistas del factor de necrosis tumoral alfa en un área endémica, ¿vale la pena el riesgo? biomedica 2007;27:159. [DOI: 10.7705/biomedica.v27i2.212] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
154 Mcrae BL, Levin AD, Wildenberg ME, Koelink PJ, Bousquet P, Mikaelian I, Sterman AS, Bryant S, D’haens G, Kamath R, Salfeld J, van den Brink GR. Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease. ECCOJC 2015;10:69-76. [DOI: 10.1093/ecco-jcc/jjv179] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
155 Villadsen LS, Skov L, Baadsgaard O. Biological response modifiers and their potential use in the treatment of inflammatory skin diseases: Biological response modifiers. Experimental Dermatology 2003;12:1-10. [DOI: 10.1034/j.1600-0625.2003.120101.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
156 D'haens G. Infliximab (Remicade ®): the magic bullet for Crohn's disease? Digestive and Liver Disease 2000;32:653-6. [DOI: 10.1016/s1590-8658(00)80324-2] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
157 Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007;6:75-92. [DOI: 10.1038/nrd2196] [Cited by in Crossref: 126] [Cited by in F6Publishing: 110] [Article Influence: 8.4] [Reference Citation Analysis]
158 Bego MG, St Jeor S. Human cytomegalovirus infection of cells of hematopoietic origin: HCMV-induced immunosuppression, immune evasion, and latency. Exp Hematol. 2006;34:555-570. [PMID: 16647557 DOI: 10.1016/j.exphem.2005.11.012] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
159 Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK. Alterations in the function of circulating mononuclear cells derived from patients with Crohn’s disease treated with mastic. World J Gastroenterol. 2007;13:6031-6036. [PMID: 18023095 DOI: 10.3748/wjg.13.6031] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
160 Filler SG, Yeaman MR, Sheppard DC. Tumor Necrosis Factor Inhibition and Invasive Fungal Infections. Clinical Infectious Diseases 2005;41:S208-12. [DOI: 10.1086/430000] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 4.3] [Reference Citation Analysis]
161 Amini Kadijani A, Asadzadeh Aghdaei H, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, Nguyen VQ, Mays JL, Reza Zali M. Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease. Clin Transl Gastroenterol 2017;8:e117. [PMID: 28914262 DOI: 10.1038/ctg.2017.44] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
162 Di Rocco P, Manco M, Rosa G, Greco AV, Mingrone G. Lowered Tumor Necrosis Factor Receptors, but Not Increased Insulin Sensitivity, with Infliximab. Obesity Research 2004;12:734-9. [DOI: 10.1038/oby.2004.86] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
163 Silva LC, Ortigosa LC, Benard G. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2010;2:817-33. [DOI: 10.2217/imt.10.67] [Cited by in Crossref: 144] [Cited by in F6Publishing: 128] [Article Influence: 12.0] [Reference Citation Analysis]
164 Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T. Adalimumab in patients with Crohn’s disease--safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther. 2007;25:787-796. [PMID: 17373917 DOI: 10.1111/j.1365-2036.2007.03253.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
165 Wrigley BJ, Lip GY, Shantsila E. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail 2011;13:1161-71. [PMID: 21952932 DOI: 10.1093/eurjhf/hfr122] [Cited by in Crossref: 115] [Cited by in F6Publishing: 109] [Article Influence: 10.5] [Reference Citation Analysis]
166 Saeed SA, Crandall WV. Managing Crohn Disease in Children and Adolescents: Focus on Tumor Necrosis Factor Antagonists. Pediatric Drugs 2008;10:31-8. [DOI: 10.2165/00148581-200810010-00004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
167 van der Vaart H, Koëter GH, Postma DS, Kauffman HF, ten Hacken NHT. First Study of Infliximab Treatment in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2005;172:465-9. [DOI: 10.1164/rccm.200501-147oc] [Cited by in Crossref: 80] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
168 Mann DL. Targeted anticytokine therapy and the failing heart. Am J Cardiol 2005;95:9C-16C; discussion 38C-40C. [PMID: 15925559 DOI: 10.1016/j.amjcard.2005.03.007] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 4.4] [Reference Citation Analysis]
169 Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119-133. [PMID: 10338381 DOI: 10.1097/00054725-199905000-00008] [Cited by in Crossref: 267] [Cited by in F6Publishing: 246] [Article Influence: 11.6] [Reference Citation Analysis]
170 Chen SK, Liao KP, Liu J, Kim SC. Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study. Arthritis Care Res (Hoboken) 2020;72:9-17. [PMID: 30570833 DOI: 10.1002/acr.23824] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
171 Gillett HR, Arnott ID, McIntyre M, Campbell S, Dahele A, Priest M, Jackson R, Ghosh S. Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology 2002;122:800-5. [PMID: 11875014 DOI: 10.1053/gast.2002.31874] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 4.3] [Reference Citation Analysis]
172 Salfeld J, Kupper H. Adalimumab. In: Boehncke W, Radeke HH, editors. Biologics in General Medicine. Berlin: Springer Berlin Heidelberg; 2007. pp. 14-31. [DOI: 10.1007/978-3-540-29018-6_3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
173 Aithal GP, Mansfield JC. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther. 2001;15:1101-1108. [PMID: 11472312 DOI: 10.1046/j.1365-2036.2001.01023.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 2.4] [Reference Citation Analysis]
174 Caviglia R, Boškoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opinion on Drug Safety 2008;7:617-32. [DOI: 10.1517/14740338.7.5.617] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
175 Lügering A, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145-1157. [PMID: 11677207 DOI: 10.1053/gast.2001.28702] [Cited by in Crossref: 402] [Cited by in F6Publishing: 377] [Article Influence: 19.1] [Reference Citation Analysis]
176 Maisey N. Antitumor necrosis factor (TNF-a) antibodies in the treatment of renal cell cancer. Cancer Invest 2007;25:589-93. [PMID: 17852116 DOI: 10.1080/07357900701359700] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
177 Ohno S, Umebayashi I, Matsukawa M, Goto T, Yano T. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan. Arthritis Res Ther 2019;21:2. [PMID: 30611312 DOI: 10.1186/s13075-018-1793-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
178 Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 2002;16:111-48. [PMID: 11985485 DOI: 10.2165/00063030-200216020-00005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 3.3] [Reference Citation Analysis]
179 Uberti JP, Ayash L, Ratanatharathorn V, Silver S, Reynolds C, Becker M, Reddy P, Cooke KR, Yanik G, Whitfield J, Jones D, Hutchinson R, Braun T, Ferrara JL, Levine JE. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:680-7. [PMID: 16125638 DOI: 10.1016/j.bbmt.2005.05.009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 53] [Article Influence: 3.9] [Reference Citation Analysis]
180 Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, To K, Harashima S, Hatta N, Harada M. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58:1248-1257. [PMID: 18438840 DOI: 10.1002/art.23447] [Cited by in Crossref: 244] [Cited by in F6Publishing: 216] [Article Influence: 17.4] [Reference Citation Analysis]
181 Irani RA, Zhang Y, Zhou CC, Blackwell SC, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-alpha signaling. Hypertension 2010;55:1246-53. [PMID: 20351341 DOI: 10.1161/HYPERTENSIONAHA.110.150540] [Cited by in Crossref: 58] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
182 Van Deventer S. Review article: targeting TNFα as a key cytokine in the inflammatory processes of Crohn’s disease - the mechanisms of action of infliximab. Alimentary Pharmacology & Therapeutics 1999;13:3-8. [DOI: 10.1046/j.1365-2036.1999.00024.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 2.8] [Reference Citation Analysis]
183 Sturm L, Schwemberger B, Menzel U, Häckel S, Albers CE, Plank C, Rip J, Alini M, Traweger A, Grad S, Basoli V. In Vitro Evaluation of a Nanoparticle-Based mRNA Delivery System for Cells in the Joint. Biomedicines 2021;9:794. [PMID: 34356857 DOI: 10.3390/biomedicines9070794] [Reference Citation Analysis]
184 Velasco-Velázquez MA, Salinas-Jazmín N, Hisaki-Itaya E, Cobos-Puc L, Xolalpa W, González G, Tenorio-Calvo A, Piña-Lara N, Juárez-Bayardo LC, Flores-Ortiz LF, Medina-Rivero E, Pérez NO, Pérez-Tapia SM. Extensive preclinical evaluation of an infliximab biosimilar candidate. Eur J Pharm Sci 2017;102:35-45. [PMID: 28188909 DOI: 10.1016/j.ejps.2017.01.038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
185 Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7:83-88. [PMID: 11383595 DOI: 10.1097/00054725-200105000-00001] [Cited by in Crossref: 288] [Cited by in F6Publishing: 267] [Article Influence: 13.7] [Reference Citation Analysis]
186 ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002;50:206-211. [PMID: 11788561 DOI: 10.1136/gut.50.2.206] [Cited by in Crossref: 370] [Cited by in F6Publishing: 358] [Article Influence: 18.5] [Reference Citation Analysis]
187 Javed Q, Murtaza I. Therapeutic Potential of Tumour Necrosis Factor-alpha Antagonists in Patients with Chronic Heart Failure. Heart, Lung and Circulation 2013;22:323-7. [DOI: 10.1016/j.hlc.2012.12.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
188 Zhang Y, Adner M, Cardell LO. IL-1beta-induced transcriptional up-regulation of bradykinin B1 and B2 receptors in murine airways. Am J Respir Cell Mol Biol 2007;36:697-705. [PMID: 17255557 DOI: 10.1165/rcmb.2005-0369OC] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
189 Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 2004;15:353-366. [PMID: 15450251 DOI: 10.1016/j.cytogfr.2004.03.011] [Cited by in Crossref: 194] [Cited by in F6Publishing: 177] [Article Influence: 11.4] [Reference Citation Analysis]
190 Dagdeviren S, Kandilci HB, Uysal B, Zeybek ND, Korkusuz P, Gümüsel B, Korkusuz F. Tumor necrosis factor-alpha antagonist administration recovers skeletal muscle dysfunction in ovariectomized rats. J Orthop Res 2011;29:275-80. [PMID: 20690186 DOI: 10.1002/jor.21226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
191 Di Sabatino A, Ciccocioppo R, Cinque B, Millimaggi D, Morera R, Ricevuti L, Cifone MG, Corazza GR. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease. Gut. 2004;53:70-77. [PMID: 14684579 DOI: 10.1136/gut.53.1.70] [Cited by in Crossref: 127] [Cited by in F6Publishing: 130] [Article Influence: 7.1] [Reference Citation Analysis]
192 Navarro Coy NC, Brown S, Bosworth A, Davies CT, Emery P, Everett CC, Fernandez C, Gray JC, Hartley S, Hulme C, Keenan AM, McCabe C, Redmond A, Reynolds C, Scott D, Sharples LD, Pavitt S, Buch MH. The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. BMC Musculoskelet Disord 2014;15:452. [PMID: 25539805 DOI: 10.1186/1471-2474-15-452] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
193 Ahmad K, Rogers S. Three years' experience with infliximab in recalcitrant psoriasis. Clin Exp Dermatol 2006;31:630-3. [DOI: 10.1111/j.1365-2230.2006.02170.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
194 Reiling N, Schneider D, Ehlers S. Mycobacterium Tuberculosis-Induced Cell Death of Primary Human Monocytes and Macrophages Is Not Significantly Modulated by Tumor Necrosis Factor-Targeted Biologicals. Journal of Investigative Dermatology Symposium Proceedings 2007;12:26-33. [DOI: 10.1038/sj.jidsymp.5650033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
195 Green LL. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods. 1999;231:11-23. [PMID: 10648924 DOI: 10.1016/s0022-1759(99)00137-4] [Cited by in Crossref: 155] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
196 Feldmann M, Elliott MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol 1997;64:283-350. [PMID: 9100984 DOI: 10.1016/s0065-2776(08)60891-3] [Cited by in Crossref: 151] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
197 Caprioli F, Bosè F, Rossi RL, Petti L, Viganò C, Ciafardini C, Raeli L, Basilisco G, Ferrero S, Pagani M, Conte D, Altomare G, Monteleone G, Abrignani S, Reali E. Reduction of CD68+ Macrophages and Decreased IL-17 Expression in Intestinal Mucosa of Patients with Inflammatory Bowel Disease Strongly Correlate With Endoscopic Response and Mucosal Healing following Infliximab Therapy: . Inflammatory Bowel Diseases 2013;19:729-39. [DOI: 10.1097/mib.0b013e318280292b] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
198 Körner H, Lemckert FA, Chaudhri G, Etteldorf S, Sedgwick JD. Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system. Eur J Immunol 1997;27:1973-81. [DOI: 10.1002/eji.1830270822] [Cited by in Crossref: 86] [Cited by in F6Publishing: 76] [Article Influence: 3.4] [Reference Citation Analysis]
199 Wolff D, Ayuk F, Elmaagacli A, Bertz H, Lawitschka A, Schleuning M, Meyer RG, Gerbitz A, Hilgendorf I, Hildebrandt GC, Edinger M, Klein S, Halter J, Mousset S, Holler E, Greinix HT. Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers. Biol Blood Marrow Transplant 2013;19:767-76. [PMID: 23376495 DOI: 10.1016/j.bbmt.2013.01.018] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
200 Mikuls TR, Moreland LW. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. Expert Opin Pharmacother 2001;2:75-84. [PMID: 11336570 DOI: 10.1517/14656566.2.1.75] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 1.9] [Reference Citation Analysis]
201 Lee MR, Cooper AJ. Biologic agents in psoriasis. Australas J Dermatol 2006;47:217-30. [DOI: 10.1111/j.1440-0960.2006.00286.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
202 Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, Ueda A, Nakamura S, Ohno S, Ishigatsubo Y. Cytokine production profile in patients with Behcet's disease treated with infliximab. Cytokine 2003;24:210-8. [DOI: 10.1016/j.cyto.2003.09.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
203 Mascheretti S, Schreiber S. Genetic Testing in Crohn Disease: Utility in Individualizing Patient Management. American Journal of PharmacoGenomics 2005;5:213-22. [DOI: 10.2165/00129785-200505040-00002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
204 Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev. 2005;57:187-215. [PMID: 15914467 DOI: 10.1124/pr.57.2.6] [Cited by in Crossref: 176] [Cited by in F6Publishing: 159] [Article Influence: 10.4] [Reference Citation Analysis]
205 Szabo TM, Frigy A, Nagy EE. Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results. Int J Mol Sci 2021;22:13053. [PMID: 34884857 DOI: 10.3390/ijms222313053] [Reference Citation Analysis]
206 Gottlieb AB, Masuda S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U, Dooley LT, Fasanmade AA, Wagner CL. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. Journal of the American Academy of Dermatology 2003;48:68-75. [DOI: 10.1067/mjd.2003.10] [Cited by in Crossref: 117] [Cited by in F6Publishing: 102] [Article Influence: 6.2] [Reference Citation Analysis]
207 Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang GB. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2011;17:1-17. [PMID: 20685255 DOI: 10.1016/j.bbmt.2010.05.011] [Cited by in Crossref: 224] [Cited by in F6Publishing: 191] [Article Influence: 18.7] [Reference Citation Analysis]
208 Semeraro F, Arcidiacono B, Nascimbeni G, Angi M, Parolini B, Costagliola C. Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis. Drug Des Devel Ther 2014;8:341-8. [PMID: 24711694 DOI: 10.2147/DDDT.S54207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
209 Miller EA, Ernst JD. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J Clin Invest 2009;119:1079-82. [PMID: 19422095 DOI: 10.1172/jci39143] [Cited by in Crossref: 52] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
210 Fries W, Muja C, Crisafulli C, Costantino G, Longo G, Cuzzocrea S, Mazzon E. Infliximab and etanercept are equally effective in reducing enterocyte APOPTOSIS in experimental colitis. Int J Med Sci 2008;5:169-80. [PMID: 18645606 DOI: 10.7150/ijms.5.169] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
211 Brande JMH, Peppelenbosch MP, Deventer SJH. Treating Crohn's Disease by Inducing T Lymphocyte Apoptosis. Annals of the New York Academy of Sciences 2002;973:166-80. [DOI: 10.1111/j.1749-6632.2002.tb04628.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
212 Viklicky O, Hruba P, Tomiuk S, Schmitz S, Gerstmayer B, Sawitzki B, Miqueu P, Mrazova P, Tycova I, Svobodova E, Honsova E, Janssen U, Volk HD, Reinke P. Sequential Targeting of CD52 and TNF Allows Early Minimization Therapy in Kidney Transplantation: From a Biomarker to Targeting in a Proof-Of-Concept Trial. PLoS One 2017;12:e0169624. [PMID: 28085915 DOI: 10.1371/journal.pone.0169624] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
213 Ochsenkühn T, Sackmann M, Göke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. European Journal of Gastroenterology & Hepatology 2004;16:1167-71. [DOI: 10.1097/00042737-200411000-00014] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 4.7] [Reference Citation Analysis]
214 Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M, Dietze L, Kronenwett R, Hünerlitürkoglu A, Haas R. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody. Bone Marrow Transplant 2001;28:47-9. [DOI: 10.1038/sj.bmt.1703094] [Cited by in Crossref: 108] [Cited by in F6Publishing: 94] [Article Influence: 5.1] [Reference Citation Analysis]
215 Bank S, Julsgaard M, Abed OK, Burisch J, Broder Brodersen J, Pedersen NK, Gouliaev A, Ajan R, Nytoft Rasmussen D, Honore Grauslund C, Roug S, Galsgaard J, Sprogøe Høyer Finsen D, Lindby K, Sørensen J, Larsen L, Rohr Andersen M, Brandslund I, Thomassen M, Green A, Bo Bojesen A, Bek Sørensen S, Vogel U, Andersen V; Danish IBD Genetics Working Group. Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease. Aliment Pharmacol Ther 2019;49:890-903. [PMID: 30811631 DOI: 10.1111/apt.15187] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
216 Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D. Infliximab in the surgical management of complex fistulating anal Crohn’s disease. Colorectal Dis. 2005;7:164-168. [PMID: 15720356 DOI: 10.1111/j.1463-1318.2004.00749.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 3.6] [Reference Citation Analysis]
217 Larkin JM, Ferguson TR, Pickering LM, Edmonds K, James MG, Thomas K, Banerji U, Berns B, de Boer C, Gore ME. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. Br J Cancer 2010;103:1149-53. [PMID: 20842130 DOI: 10.1038/sj.bjc.6605889] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
218 Hitraya E, Schaible T. Anti – Tumor Necrosis Factor Therapies In Crohn’s Disease And Rheumatoid Arthritis. In: Ciliberto G, Savino R, editors. Cytokine Inhibitors. CRC Press; 2000. [DOI: 10.1201/9780203904244.ch4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
219 Petito V, Lopetuso LR, Arena V, Stigliano E, Boninsegna A, Bibbò S, Poscia A, Alfieri S, Rosa F, Amato A. Direct effect of infliximab on intestinal mucosa sustains mucosal healing: exploring new mechanisms of action. Dig Liver Dis. 2016;48:391-398. [PMID: 26804809 DOI: 10.1016/j.dld.2015.12.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
220 Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010;10:301-16. [PMID: 20414204 DOI: 10.1038/nri2761] [Cited by in Crossref: 604] [Cited by in F6Publishing: 553] [Article Influence: 50.3] [Reference Citation Analysis]
221 Anderson P, Louie J, Lau A, Broder M. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Curr Rheumatol Rep 2005;7:3-9. [PMID: 15760575 DOI: 10.1007/s11926-005-0002-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
222 Saulsbury FT, Mann JA. Treatment with infliximab for a child with Behçet's disease. Arthritis Rheum 2003;49:599-600. [PMID: 12910569 DOI: 10.1002/art.11204] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
223 Sibilia J. Protéine de fusion ou anticorps monoclonal: Quel biomédicament choisir dans une maladie inflammatoire ? Med Sci (Paris) 2009;25:1033-8. [DOI: 10.1051/medsci/200925121033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
224 Weaver AL. Differentiating the new rheumatoid arthritis biologic therapies. J Clin Rheumatol 2003;9:99-114. [PMID: 17041440 DOI: 10.1097/01.RHU.0000062513.64012.1d] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
225 Farrell RJ, Banerjee S, Peppercorn MA. Recent advances in inflammatory bowel disease. Crit Rev Clin Lab Sci 2001;38:33-108. [PMID: 11256517 DOI: 10.1080/20014091084173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
226 Zubaidi A, Buie WD, Hart DA, Sigalet D. Temporal Expression of Cytokines in Rat Cutaneous, Fascial, and Intestinal Wounds: A Comparative Study. Dig Dis Sci 2010;55:1581-8. [DOI: 10.1007/s10620-009-0931-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
227 Mufti AH, Toye BW, Mckendry RR, Angel JB. Mycobacterium abscessus infection after use of tumor necrosis factor α inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor α inhibitor use. Diagnostic Microbiology and Infectious Disease 2005;53:233-8. [DOI: 10.1016/j.diagmicrobio.2005.06.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
228 Zanger P, Kötter I, Kremsner P, Gabrysch S. Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe. Clinical Microbiology and Infection 2012;18:670-6. [DOI: 10.1111/j.1469-0691.2011.03674.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
229 Drewe E, Powell RJ. Clinically useful monoclonal antibodies in treatment. J Clin Pathol 2002;55:81-5. [PMID: 11864998 DOI: 10.1136/jcp.55.2.81] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
230 Martínez NO, Noiseux RC, Martín CJA, Lara GV. Reactivation Tuberculosis in a Patient With Anti–TNF-α Treatment. American Journal of Gastroenterology 2001;96:1665-6. [DOI: 10.1111/j.1572-0241.2001.03836.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 44] [Article Influence: 1.5] [Reference Citation Analysis]
231 Segueni N, Benmerzoug S, Rose S, Gauthier A, Bourigault ML, Reverchon F, Philippeau A, Erard F, Le Bert M, Bouscayrol H, Wachter T, Garcia I, Kollias G, Jacobs M, Ryffel B, Quesniaux VF. Innate myeloid cell TNFR1 mediates first line defence against primary Mycobacterium tuberculosis infection. Sci Rep 2016;6:22454. [PMID: 26931771 DOI: 10.1038/srep22454] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
232 Abbate A, Van Tassell BW, Biondi-Zoccai GG. Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events. BioDrugs 2012;26:217-33. [PMID: 22571369 DOI: 10.1007/BF03261881] [Cited by in Crossref: 45] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
233 Matera MG, Calzetta L, Cazzola M. TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm Pharmacol Ther. 2010;23:121-128. [PMID: 19853667 DOI: 10.1016/j.pupt.2009.10.007] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 6.4] [Reference Citation Analysis]
234 Plenge RM, Criswell LA. Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. Curr Opin Rheumatol 2008;20:145-52. [PMID: 18349743 DOI: 10.1097/BOR.0b013e3282f5135b] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
235 Sporter RJ, Kim JH, Frishman WH. Device-based nonspecific immunomodulation therapy (Celacade), and its potential role in the treatment of chronic heart failure. Cardiol Rev 2008;16:280-7. [PMID: 18923231 DOI: 10.1097/CRD.0b013e318188591c] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
236 Nussenblatt RB, Byrnes G, Sen HN, Yeh S, Faia L, Meyerle C, Wroblewski K, Li Z, Liu B, Chew E, Sherry PR, Friedman P, Gill F, Ferris F 3rd. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina 2010;30:1579-87. [PMID: 20847709 DOI: 10.1097/IAE.0b013e3181e7978e] [Cited by in Crossref: 55] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
237 Brown S, Everett CC, Naraghi K, Davies C, Dawkins B, Hulme C, McCabe C, Pavitt S, Emery P, Sharples L, Buch MH. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technol Assess 2018;22:1-280. [PMID: 29900829 DOI: 10.3310/hta22340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
238 Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn’s disease. Gut. 2002;50:196-200. [PMID: 11788559 DOI: 10.1136/gut.50.2.196] [Cited by in Crossref: 89] [Cited by in F6Publishing: 93] [Article Influence: 4.5] [Reference Citation Analysis]
239 Meroni PL, Valesini G. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective. BioDrugs 2014;28 Suppl 1:S5-13. [PMID: 24687234 DOI: 10.1007/s40259-013-0063-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
240 Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfeld J, Sasso EH. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131:308-316. [PMID: 19188093 DOI: 10.1016/j.clim.2009.01.002] [Cited by in Crossref: 210] [Cited by in F6Publishing: 183] [Article Influence: 16.2] [Reference Citation Analysis]
241 Winterfield LS, Menter A. Infliximab. Dermatol Ther 2004;17:409-26. [DOI: 10.1111/j.1396-0296.2004.04044.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
242 Coquet-Reinier B, Berdah SV, Grimaud JC, Birnbaum D, Cougard PA, Barthet M, Desjeux A, Moutardier V, Brunet C. Preoperative infliximab treatment and postoperative complications after laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis: a case-matched study. Surg Endosc. 2010;24:1866-1871. [PMID: 20108148 DOI: 10.1007/s00464-009-0861-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
243 Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M. New biologic therapeutics for ulcerative colitis and Crohn’s disease. Expert Opin Biol Ther. 2014;14:583-600. [PMID: 24502344 DOI: 10.1517/14712598.2014.885945] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
244 Raza A, Venugopal P, Gezer S, Gregory SA, Dong L, Leurgens S, Mundle SD, Shetty VT, Alvi S, Ali A, Span L, Dar SE, Hines C, Hsu WT, Loew J, Borok RZ, Hernandez B, Robin E, Rifkin S, Alston D, Shah R, Preisler HD. Pilot Study of Pentoxifylline and Ciprofloxacin with or without Dexamenthasone Produces Encouraging Results in Myelodysplastic Syndromes. In: Hiddemann W, Büchner T, Wörmann B, Ritter J, Creutzig U, Keating M, Plunkett W, editors. Acute Leukemias VII. Berlin: Springer Berlin Heidelberg; 1998. pp. 42-51. [DOI: 10.1007/978-3-642-71960-8_5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
245 Harrison J, Hanauer SB. Medical treatment of Crohn's disease. Gastroenterology Clinics of North America 2002;31:167-84. [DOI: 10.1016/s0889-8553(01)00011-5] [Cited by in Crossref: 9] [Article Influence: 0.5] [Reference Citation Analysis]
246 Ducharme J, Pelletier C, Zacharias R. The safety of infliximab infusions in the community setting. Can J Gastroenterol 2010;24:307-11. [PMID: 20485705 DOI: 10.1155/2010/138456] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
247 Dessinioti C, Stratigos AJ, Katsambas A, Antoniou C. Anti-tumor necrosis factor-α therapies for immune-mediated and inflammatory skin diseases. Drug Dev Res 2011;72:615-22. [DOI: 10.1002/ddr.20471] [Reference Citation Analysis]
248 Actis GC, Pellicano R, Fagoonee S, Ribaldone DG. History of Inflammatory Bowel Diseases. J Clin Med. 2019;8:1970. [PMID: 31739460 DOI: 10.3390/jcm8111970] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 10.3] [Reference Citation Analysis]
249 Schleyer V, Landthaler M, Szeimies R. Novel pharmacological approaches in the treatment of psoriasis. J Eur Acad Dermatol Venerol 2005;19:1-20. [DOI: 10.1111/j.1468-3083.2004.01070.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
250 Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection. Seminars in Arthritis and Rheumatism 2006;36:159-67. [DOI: 10.1016/j.semarthrit.2006.02.001] [Cited by in Crossref: 157] [Cited by in F6Publishing: 134] [Article Influence: 9.8] [Reference Citation Analysis]
251 Gay RD, Clarke AW, Elgundi Z, Domagala T, Simpson RJ, Le NB, Doyle AG, Jennings PA. Anti-TNFα domain antibody construct CEP-37247: Full antibody functionality at half the size. MAbs 2010;2:625-38. [PMID: 20930515 DOI: 10.4161/mabs.2.6.13493] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
252 Shi YH, Weng Y, Liu ZJ. Detection of serum infliximab concentration for evaluation of treatment efficacy in inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2015; 23(31): 4946-4953 [DOI: 10.11569/wcjd.v23.i31.4946] [Reference Citation Analysis]
253 Koizumi K, Hoshiai M, Katsumata N, Toda T, Kise H, Hasebe Y, Kono Y, Sunaga Y, Yoshizawa M, Watanabe A, Kagami K, Abe M, Sugita K. Infliximab regulates monocytes and regulatory T cells in Kawasaki disease. Pediatr Int 2018;60:796-802. [PMID: 29543362 DOI: 10.1111/ped.13555] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
254 Cardoso Santos R, Nasser Figueiredo V, Cláudio Martins L, Haro Moraes CD, Quinaglia T, Boer-martins L, Ferreira-melo SE, Alexandre Yazbek M, Bertolo M, Moreno Junior H. Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure. Revista da Associação Médica Brasileira 2012;58:698-702. [DOI: 10.1590/s0104-42302012000600015] [Cited by in Crossref: 6] [Article Influence: 0.6] [Reference Citation Analysis]
255 Sodhi M, Pearson K, White ES, Culver DA. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respiratory Medicine 2009;103:268-73. [DOI: 10.1016/j.rmed.2008.08.016] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 4.9] [Reference Citation Analysis]
256 Mascheretti S, Hampe J, Kühbacher T, Herfarth H, Krawczak M, Fölsch UR, Schreiber S. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn’s disease treated with infliximab. Pharmacogenomics J. 2002;2:127-136. [PMID: 12049175 DOI: 10.1038/sj.tpj.6500091] [Cited by in Crossref: 107] [Cited by in F6Publishing: 96] [Article Influence: 5.4] [Reference Citation Analysis]
257 Seitz G, Warmann SW, Guglielmetti A, Heitmann H, Ruck P, Kreis ME, Fuchs J. Protective effect of tumor necrosis factor alpha antibody on experimental necrotizing enterocolitis in the rat. J Pediatr Surg. 2005;40:1440-1445. [PMID: 16150346 DOI: 10.1016/j.jpedsurg.2005.05.043] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
258 Mcnamara D, Brophy S, Hyland J. Perianal Crohn's disease and infliximab therapy. The Surgeon 2004;2:258-63. [DOI: 10.1016/s1479-666x(04)80094-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
259 Moriconi F, Malik IA, Amanzada A, Blaschke M, Raddatz D, Khan S, Ramadori G. The anti-TNF-α antibody infliximab indirectly regulates PECAM-1 gene expression in two models of in vitro blood cell activation. Lab Invest 2012;92:166-77. [PMID: 22042082 DOI: 10.1038/labinvest.2011.160] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
260 Park H, Solis NV, Louie JS, Spellberg B, Rodriguez N, Filler SG. Different tumor necrosis factor α antagonists have different effects on host susceptibility to disseminated and oropharyngeal candidiasis in mice. Virulence 2014;5:625-9. [PMID: 25007095 DOI: 10.4161/viru.29699] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
261 Doan T, Massarotti E. Rheumatoid arthritis: an overview of new and emerging therapies. J Clin Pharmacol 2005;45:751-62. [PMID: 15951465 DOI: 10.1177/0091270005277938] [Cited by in Crossref: 104] [Cited by in F6Publishing: 92] [Article Influence: 6.1] [Reference Citation Analysis]
262 Morales-lara MJ, Cañete JD, Torres-moreno D, Hernández MV, Pedrero F, Celis R, García-simón MS, Conesa-zamora P. Effets des polymorphismes des gènes TRAILR1 et TNFR1A sur la réponse au traitement anti-TNF chez les patients atteints de polyarthrite rhumatoïde et de rhumatisme psoriasique. Revue du Rhumatisme 2012;79:545-50. [DOI: 10.1016/j.rhum.2012.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
263 Reguia?? Z, Grange F. The Role of Anti-Tumor Necrosis Factor-?? Therapy in Pyoderma Gangrenosum Associated with Inflammatory Bowel Disease: . American Journal of Clinical Dermatology 2007;8:67-77. [DOI: 10.2165/00128071-200708020-00002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
264 Sozutek A, Ozyazici S, Colak T, Cetınkunar S, Irkorucu O, Bobusoglu O, Cennet A. Evaluating the effect of infliximab on the healing of left colonic anastomosis in the presence of intra-abdominal sepsis. Arab Journal of Gastroenterology 2016;17:84-9. [DOI: 10.1016/j.ajg.2016.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
265 Quetglas EG, Mujagic Z, Wigge S, Keszthelyi D, Wachten S, Masclee A, Reinisch W. Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease. World J Gastroenterol 2015; 21(44): 12519-12543 [PMID: 26640330 DOI: 10.3748/wjg.v21.i44.12519] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
266 Agnholt J, Dahlerup JF, Kaltoft K. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 2003;23:76-85. [PMID: 12906870 DOI: 10.1016/s1043-4666(03)00201-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
267 Balakumar P, Singh M. Anti-tumour necrosis factor-alpha therapy in heart failure: future directions. Basic Clin Pharmacol Toxicol 2006;99:391-7. [PMID: 17169118 DOI: 10.1111/j.1742-7843.2006.pto_508.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
268 Kohno T, Tam LT, Stevens SR, Louie JS. Binding Characteristics of Tumor Necrosis Factor Receptor-Fc Fusion Proteins vs Anti-Tumor Necrosis Factor mAbs. Journal of Investigative Dermatology Symposium Proceedings 2007;12:5-8. [DOI: 10.1038/sj.jidsymp.5650034] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 3.6] [Reference Citation Analysis]
269 Benucci M, Saviola G, Baiardi P, Manfredi M, Sarzi Puttini P, Atzeni F. Determinants of Risk Infection During Therapy with Anti TNF-Alpha Blocking Agents in Rheumatoid Arthritis. Open Rheumatol J 2012;6:33-7. [PMID: 22655000 DOI: 10.2174/1874312901206010033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
270 Murthy S, Cooper HS, Yoshitake H, Meyer C, Meyer CJ, Murthy NS. Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis. Aliment Pharmacol Ther. 1999;13:251-260. [PMID: 10102957 DOI: 10.1046/j.1365-2036.1999.00457.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 2.3] [Reference Citation Analysis]
271 Casellas i Jordà F. [TNF-alpha inhibitors in inflammatory bowel disease]. Med Clin (Barc) 2004;123:627-34. [PMID: 15546523 DOI: 10.1016/s0025-7753(04)74622-9] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
272 Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133-3140. [PMID: 12796126 DOI: 10.1161/01.cir.0000077913.60364.d2] [Cited by in Crossref: 986] [Cited by in F6Publishing: 350] [Article Influence: 51.9] [Reference Citation Analysis]
273 Scardapane A, Breda L, Lucantoni M, Chiarelli F. TNF-α Polymorphisms in Juvenile Idiopathic Arthritis: Which Potential Clinical Implications? Int J Rheumatol 2012;2012:756291. [PMID: 23133455 DOI: 10.1155/2012/756291] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
274 Kozuch PL, Hanauer SB. General Principles and Pharmacology of Biologics in Inflammatory Bowel Disease. Gastroenterology Clinics of North America 2006;35:757-73. [DOI: 10.1016/j.gtc.2006.09.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
275 Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. The Journal of Pediatrics 2000;137:192-6. [DOI: 10.1067/mpd.2000.107161] [Cited by in Crossref: 102] [Cited by in F6Publishing: 100] [Article Influence: 4.6] [Reference Citation Analysis]
276 Sands BE. Therapy of inflammatory bowel disease. Gastroenterology. 2000;118:S68-S82. [PMID: 10868899 DOI: 10.1016/s0016-5085(00)70007-2] [Cited by in Crossref: 165] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
277 García-lechuz Moya JM. Complicaciones infecciosas asociadas al uso de fármacos antagonistas del factor de necrosis tumoral. Revisión de conjunto. Enfermedades Infecciosas y Microbiología Clínica 2005;23:551-9. [DOI: 10.1157/13080266] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
278 Rozenbaum M, Boulman N, Slobodin G, Ayubkhanov E, Rosner I. Polyarthritis flare complicating rheumatoid arthritis infliximab therapy: a paradoxic adverse reaction. J Clin Rheumatol 2006;12:269-71. [PMID: 17149054 DOI: 10.1097/01.rhu.0000250241.91842.b6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
279 Saleem B, Mackie S, Emery P. Infliximab for rheumatoid arthritis. Expert Review of Clinical Immunology 2014;2:193-207. [DOI: 10.1586/1744666x.2.2.193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
280 Feldman AM, Mctiernan C. Is There Any Future for Tumor Necrosis Factor Antagonists in Chronic Heart Failure?: . American Journal of Cardiovascular Drugs 2004;4:11-9. [DOI: 10.2165/00129784-200404010-00002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
281 Sakai H, Yamada Y, Shimizu M, Saito K, Moriwaki H, Hara A. Genetic ablation of Tnfα demonstrates no detectable suppressive effect on inflammation-related mouse colon tumorigenesis. Chemico-Biological Interactions 2010;184:423-30. [DOI: 10.1016/j.cbi.2010.01.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
282 Menegatti S, Bianchi E, Rogge L. Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses. Front Immunol 2019;10:382. [PMID: 30941119 DOI: 10.3389/fimmu.2019.00382] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
283 Palamides P, Jodeleit H, Föhlinger M, Beigel F, Herbach N, Mueller T, Wolf E, Siebeck M, Gropp R. A mouse model for ulcerative colitis based on NOD-scid IL2R γnull mice reconstituted with peripheral blood mononuclear cells from affected individuals. Dis Model Mech 2016;9:985-97. [PMID: 27491073 DOI: 10.1242/dmm.025452] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
284 Chantry D. Tumour necrosis factor antagonists. Emerging Drugs 2005;4:5-13. [DOI: 10.1517/14728214.4.1.5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
285 Olsen T, Cui G, Goll R, Husebekk A, Florholmen J. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol. 2009;44:727-735. [PMID: 19294580 DOI: 10.1080/00365520902803507] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
286 Kanayama K, Nakamura K, Ogino H, Sumida Y, Ihara E, Akiho H, Takayanagi R. Th1 Responses Are More Susceptible to Infliximab-Mediated Immunosuppression Than Th17 Responses. Dig Dis Sci 2011;56:3525-33. [DOI: 10.1007/s10620-011-1780-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
287 Föhlinger M, Palamides P, Mansmann U, Beigel F, Siebeck M, Gropp R. Immunological profiling of patients with ulcerative colitis leads to identification of two inflammatory conditions and CD1a as a disease marker. J Transl Med 2016;14:310. [PMID: 27809916 DOI: 10.1186/s12967-016-1048-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
288 Lacki JK. Management of the Patient with Severe Refractory Rheumatoid Arthritis: Are the Newer Treatment Options Worth Considering? BioDrugs 2000;13:425-35. [DOI: 10.2165/00063030-200013060-00006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
289 Cardoso Santos R, Nasser Figueiredo V, Cláudio Martins L, Haro Moraes CD, Quinaglia T, Boer-martins L, Ferreira-melo SE, Alexandre Yazbek M, Bertolo M, Moreno Junior H. Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure. Revista da Associação Médica Brasileira 2012;58:698-702. [DOI: 10.1016/s0104-4230(12)70274-9] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
290 Kavanaugh AF. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998;24:593-614. [PMID: 9710889 DOI: 10.1016/s0889-857x(05)70028-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
291 Clark M, Colombel J, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006. Gastroenterology 2007;133:312-39. [DOI: 10.1053/j.gastro.2007.05.006] [Cited by in Crossref: 157] [Cited by in F6Publishing: 145] [Article Influence: 10.5] [Reference Citation Analysis]
292 Lee YH, Ji JD, Bae SC, Song GG. Associations between tumor necrosis factor-alpha (TNF-alpha) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update. J Rheumatol. 2010;37:740-746. [PMID: 20194454 DOI: 10.3899/jrheum.090707] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
293 Adán A, Hernandez V, Ortiz S, Molina JJ, Pelegrin L, Espinosa G, Sanmartí R. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusions. Int Ophthalmol 2010;30:577-81. [DOI: 10.1007/s10792-010-9372-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
294 Mössner R, Schön MP, Reich K. Tumor necrosis factor antagonists in the therapy of psoriasis. Clinics in Dermatology 2008;26:486-502. [DOI: 10.1016/j.clindermatol.2007.10.030] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
295 Thomas CW, Weinshenker BG, Sandborn WJ. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004;10:28-31. [PMID: 15058523 DOI: 10.1097/00054725-200401000-00004] [Cited by in Crossref: 85] [Cited by in F6Publishing: 74] [Article Influence: 4.7] [Reference Citation Analysis]
296 Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. The Lancet Infectious Diseases 2008;8:601-11. [DOI: 10.1016/s1473-3099(08)70227-5] [Cited by in Crossref: 191] [Cited by in F6Publishing: 56] [Article Influence: 13.6] [Reference Citation Analysis]
297 Shealy DJ, Visvanathan S. Anti-TNF antibodies: lessons from the past, roadmap for the future. Handb Exp Pharmacol. 2008;101-129. [PMID: 18071943 DOI: 10.1007/978-3-540-73259-4_5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
298 Durrani K, Zakka FR, Ahmed M, Memon M, Siddique SS, Foster CS. Systemic Therapy With Conventional and Novel Immunomodulatory Agents for Ocular Inflammatory Disease. Survey of Ophthalmology 2011;56:474-510. [DOI: 10.1016/j.survophthal.2011.05.003] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
299 Lee FF, Foster CS. Pharmacotherapy of uveitis. Expert Opin Pharmacother 2010;11:1135-46. [PMID: 20367272 DOI: 10.1517/14656561003713534] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
300 Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol. 2012;67:1349-1361. [PMID: 22727462 DOI: 10.1016/j.jaad.2012.04.036] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
301 Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, Hildner K, Hoffman A, Kiesslich R, Rink AD. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14+ macrophages. Gastroenterology. 2011;141:2026-2038. [PMID: 21875498 DOI: 10.1053/j.gastro.2011.08.032] [Cited by in Crossref: 140] [Cited by in F6Publishing: 144] [Article Influence: 12.7] [Reference Citation Analysis]
302 D'haens GR. Infliximab as disease-modifying therapy: . European Journal of Gastroenterology & Hepatology 2003;15:233-7. [DOI: 10.1097/00042737-200303000-00004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
303 Jacobsohn DA, Hallick J, Anders V, Mcmillan S, Morris L, Vogelsang GB. Infliximab for steroid-refractory acute GVHD: A case series. Am J Hematol 2003;74:119-24. [DOI: 10.1002/ajh.10392] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 3.5] [Reference Citation Analysis]
304 Van Assche G, Rutgeerts P. Anti-TNF agents in Crohn's disease. Expert Opin Investig Drugs. 2000;9:103-111. [PMID: 11060664 DOI: 10.1517/13543784.9.1.103] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 2.2] [Reference Citation Analysis]
305 Ramien ML, Wong A, Keystone JS. Severe Refractory Erythema Nodosum Leprosum Successfully Treated with the Tumor Necrosis Factor Inhibitor Etanercept. Clinical Infectious Diseases 2011;52:e133-5. [DOI: 10.1093/cid/ciq213] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
306 Vermeire S, van Assche G, Rutgeerts P. Review article: Altering the natural history of Crohn’s disease--evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25:3-12. [PMID: 17229216 DOI: 10.1111/j.1365-2036.2006.03134.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 36] [Article Influence: 0.7] [Reference Citation Analysis]
307 Ali H, Collnot E, Windbergs M, Lehr C. Nanomedicines for the treatment of inflammatory bowel diseases. European Journal of Nanomedicine 2013;5. [DOI: 10.1515/ejnm-2013-0004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
308 Kanakaraj P, Puffer BA, Yao XT, Kankanala S, Boyd E, Shah RR, Wang G, Patel D, Krishnamurthy R, Kaithamana S, Smith RG, LaFleur DW, Barbas CF 3rd, Hilbert DM, Kiener PA, Roschke VV. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs 2012;4:600-13. [PMID: 22864384 DOI: 10.4161/mabs.21227] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
309 Feletar M, Foley P, Brown MA. Developments in psoriasis and psoriatic arthritis. Drug Discovery Today: Disease Mechanisms 2008;5:e47-54. [DOI: 10.1016/j.ddmec.2008.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
310 Ternant D, Pfister M, Le Tilly O, Mulleman D, Picon L, Willot S, Passot C, Bejan-Angoulvant T, Lecomte T, Paintaud G, Koch G. Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model. Clin Pharmacokinet 2021. [PMID: 34351609 DOI: 10.1007/s40262-021-01057-3] [Reference Citation Analysis]
311 Gottlieb AB. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 2005;4:19-34. [DOI: 10.1038/nrd1607] [Cited by in Crossref: 102] [Cited by in F6Publishing: 95] [Article Influence: 6.0] [Reference Citation Analysis]
312 Harriman G, Harper LK, Schaible TF. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann Rheum Dis 1999;58 Suppl 1:I61-4. [PMID: 10577975 DOI: 10.1136/ard.58.2008.i61] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 1.7] [Reference Citation Analysis]
313 Kazlow Stern D, Tripp JM, Ho VC, Lebwohl M. The Use of Systemic Immune Moderators in Dermatology: An Update. Dermatologic Clinics 2005;23:259-300. [DOI: 10.1016/j.det.2004.09.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
314 Khan A, Scott DL. Certolizumab in the long-term treatment of rheumatoid arthritis. Open Access Rheumatol 2011;3:63-71. [PMID: 27790005 DOI: 10.2147/OARRR.S14556] [Reference Citation Analysis]
315 Alsalameh, Winter, Al-ward, Wendler, Kalden, Kinne. Distribution of TNF-?, TNF-R55 and TNF-R75 in the Rheumatoid Synovial Membrane: TNF Receptors are Localized Preferentially in the Lining Layer; TNF-? is Distributed Mainly in the Vicinity of TNF Receptors in the Deeper Layers. Scand J Immunol 1999;49:278-85. [DOI: 10.1046/j.1365-3083.1999.00458.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 1.0] [Reference Citation Analysis]
316 Su C, Lichtenstein GR. Recent developments in inflammatory bowel disease. Med Clin North Am. 2002;86:1497-1523. [PMID: 12510462 DOI: 10.1016/s0025-7125(02)00085-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
317 Stasi R, Amadori S, Newland AC, Provan D. Infliximab chimeric antitumor necrosis factor-α monoclonal antibody as potential treatment for myelodysplastic syndromes. Leukemia & Lymphoma 2009;46:509-16. [DOI: 10.1080/10428190400027829] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
318 Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006;4:1255-1258. [PMID: 17045211 DOI: 10.1016/j.cgh.2006.07.018] [Cited by in Crossref: 198] [Cited by in F6Publishing: 164] [Article Influence: 13.2] [Reference Citation Analysis]
319 Arnott ID, Shand A, Ghosh S. Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4. Am J Gastroenterology 2000;95:3326-7. [DOI: 10.1111/j.1572-0241.2000.03325.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
320 Sobczak M, Fabisiak A, Murawska N, Wesołowska E, Wierzbicka P, Wlazłowski M, Wójcikowska M, Zatorski H, Zwolińska M, Fichna J. Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases. Pharmacol Rep 2014;66:766-75. [PMID: 25149979 DOI: 10.1016/j.pharep.2014.04.005] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
321 Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, Xaubet A, Bosch X; BIOGEAS Study Group. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med 2011;124:386-94. [PMID: 21531225 DOI: 10.1016/j.amjmed.2010.11.028] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
322 Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheumatic Disease Clinics of North America 2003;29:185-202. [DOI: 10.1016/s0889-857x(02)00101-1] [Cited by in Crossref: 78] [Cited by in F6Publishing: 10] [Article Influence: 4.1] [Reference Citation Analysis]
323 Chan JJ, Gebauer K. Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab). Australas J Dermatol 2003;44:116-20. [DOI: 10.1046/j.1440-0960.2003.00656.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
324 Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004;50:372-379. [PMID: 14872478 DOI: 10.1002/art.20009] [Cited by in Crossref: 298] [Cited by in F6Publishing: 251] [Article Influence: 16.6] [Reference Citation Analysis]
325 Kameoka Y, Kishi F, Koura M, Yamakawa Y, Nagasawa R, Ito F, Matsuda J, Suzuki O, Nakayama T, Suzuki K. Efficacy of a recombinant single-chain fragment variable region, VasSF, as a new drug for vasculitis. Drug Des Devel Ther 2019;13:555-68. [PMID: 30787596 DOI: 10.2147/DDDT.S188651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
326 Rutgeerts P, Van Deventer S, Schreiber S. The expanding role of biological agents in the treatment of inflammatory bowel disease - focus on selective adhesion molecule inhibition: REVIEW: BIOLOGICAL STRATEGIES IN INFLAMMATORY BOWEL DISEASE. Alimentary Pharmacology & Therapeutics 2003;17:1435-50. [DOI: 10.1046/j.1365-2036.2003.01603.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
327 Hamaguchi T, Wakabayashi H, Matsumine A, Sudo A, Uchida A. TNF inhibitor suppresses bone metastasis in a breast cancer cell line. Biochem Biophys Res Commun. 2011;407:525-530. [PMID: 21414299 DOI: 10.1016/j.bbrc.2011.03.051] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
328 Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61:486-504. [PMID: 19628303 DOI: 10.1016/j.jaad.2008.10.060] [Cited by in Crossref: 124] [Cited by in F6Publishing: 92] [Article Influence: 9.5] [Reference Citation Analysis]
329 Lin TS, Byrd JC. Monoclonal Antibody Therapy in Lymphoid Leukemias. Treatment of Leukemia and Lymphoma. Elsevier; 2004. pp. 127-67. [DOI: 10.1016/s1054-3589(04)51006-2] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
330 Hsu L, Armstrong AW. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res 2014;2014:283617. [PMID: 24883332 DOI: 10.1155/2014/283617] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 8.4] [Reference Citation Analysis]
331 Collins ES, Butt AQ, Gibson DS, Dunn MJ, Fearon U, van Kuijk AW, Gerlag DM, Pontifex E, Veale DJ, Tak PP, FitzGerald O, Pennington SR. A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-α treatment of psoriatic arthritis. Proteomics Clin Appl 2016;10:645-62. [PMID: 26108918 DOI: 10.1002/prca.201500051] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
332 Balasubramanian V, Mehta G, Jones H, Sharma V, Davies NA, Jalan R, Mookerjee RP. Post-Transcriptional Regulation of Hepatic DDAH1 with TNF Blockade Leads to Improved eNOS Function and Reduced Portal Pressure In Cirrhotic Rats. Sci Rep 2017;7:17900. [PMID: 29263339 DOI: 10.1038/s41598-017-18094-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
333 Siddique SS, Shah R, Suelves AM, Foster CS. Road to remission: a comprehensive review of therapy in uveitis. Expert Opin Investig Drugs 2011;20:1497-515. [PMID: 21936708 DOI: 10.1517/13543784.2011.617741] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
334 Fischer JA, Hueber AJ, Wilson S, Galm M, Baum W, Kitson C, Auer J, Lorenz SH, Moelleken J, Bader M, Tissot AC, Tan SL, Seeber S, Schett G. Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol 2015;67:51-62. [PMID: 25303306 DOI: 10.1002/art.38896] [Cited by in Crossref: 110] [Cited by in F6Publishing: 105] [Article Influence: 15.7] [Reference Citation Analysis]
335 Caviglia R, Boskoski I, Cicala M. Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics 2009;3:39-49. [PMID: 19707394 DOI: 10.2147/btt.2009.2763] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
336 Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. Ann Rheum Dis 1999;58 Suppl 1:I70-2. [PMID: 10577977 DOI: 10.1136/ard.58.2008.i70] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 3.0] [Reference Citation Analysis]
337 Van Deventer SJ. Tumour necrosis factor and Crohn’s disease. Gut. 1997;40:443-448. [PMID: 9176068 DOI: 10.1136/gut.51.3.362] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
338 Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology. 2003;124:1774-1785. [PMID: 12806611 DOI: 10.1016/s0016-5085(03)00382-2] [Cited by in Crossref: 531] [Cited by in F6Publishing: 125] [Article Influence: 27.9] [Reference Citation Analysis]
339 Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respiratory Medicine 2006;100:2053-9. [DOI: 10.1016/j.rmed.2006.02.017] [Cited by in Crossref: 77] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
340 Winsauer C, Kruglov AA, Chashchina AA, Drutskaya MS, Nedospasov SA. Cellular sources of pathogenic and protective TNF and experimental strategies based on utilization of TNF humanized mice. Cytokine & Growth Factor Reviews 2014;25:115-23. [DOI: 10.1016/j.cytogfr.2013.12.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
341 Nogueira MC, Azevedo AM, Pereira SC, Ferreira JL, Lerner D, Lobo AM, Tavares RC, Tabak DG, Lorenzi N, Renault IZ, Bouzas LF. Anti-tumor necrosis factor-a for the treatment of steroid-refractory acute graft-versus-host disease. Braz J Med Biol Res 2007;40:1623-9. [PMID: 17713663 DOI: 10.1590/s0100-879x2006005000145] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
342 Kanai T, Totsuka T, Tezuka K, Watanabe M. ICOS costimulation in inflammatory bowel disease. J Gastroenterol 2002;37 Suppl 14:78-81. [PMID: 12572871 DOI: 10.1007/BF03326419] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
343 Olmarker K. Neovascularization and neoinnervation of subcutaneously placed nucleus pulposus and the inhibitory effects of certain drugs. Spine (Phila Pa 1976) 2005;30:1501-4. [PMID: 15990663 DOI: 10.1097/01.brs.0000167823.17687.ec] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
344 Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN Jr, Mannick EE. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001;35:823-8. [PMID: 11485127 DOI: 10.1345/aph.10395] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 3.2] [Reference Citation Analysis]
345 Armstrong AM, Gardiner KR, Kirk SJ, Halliday MI, Rowlands BJ. Tumour necrosis factor and inflammatory bowel disease. Br J Surg 1997;84:1051-8. [DOI: 10.1002/bjs.1800840805] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
346 Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C, Timotheadou E. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol. 2007;25:4542-4549. [PMID: 17925549 DOI: 10.1200/jco.2007.11.2136] [Cited by in Crossref: 158] [Cited by in F6Publishing: 80] [Article Influence: 10.5] [Reference Citation Analysis]
347 Shah B, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:607-20. [PMID: 20594134 DOI: 10.1586/eci.10.45] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
348 Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease: Pathophysiology, clinical manifestations, and management. Cancer 2004;101:1936-46. [DOI: 10.1002/cncr.20613] [Cited by in Crossref: 152] [Cited by in F6Publishing: 124] [Article Influence: 8.4] [Reference Citation Analysis]
349 Ringheanu M, Daum F, Markowitz J, Levine J, Katz S, Lin X, Silver J. Effects of Infliximab on Apoptosis and Reverse Signaling of Monocytes from Healthy Individuals and Patients with Crohn’s Disease: . Inflammatory Bowel Diseases 2004;10:801-10. [DOI: 10.1097/00054725-200411000-00015] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 2.7] [Reference Citation Analysis]
350 Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534-542. [PMID: 15389187 DOI: 10.1016/j.jaad.2004.02.021] [Cited by in Crossref: 400] [Cited by in F6Publishing: 348] [Article Influence: 23.5] [Reference Citation Analysis]
351 Wang Q, Wen Z, Cao Q. Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis. Exp Ther Med 2016;12:1693-704. [PMID: 27588089 DOI: 10.3892/etm.2016.3548] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
352 Stevens SR, Chang TH. History of development of TNF inhibitors. In: Weinberg JM, Buchholz R, editors. TNF-alpha Inhibitors. Basel: Birkhäuser-Verlag; 2006. pp. 9-22. [DOI: 10.1007/3-7643-7438-1_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
353 Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis: . Current Opinion in Rheumatology 2003;15:380-6. [DOI: 10.1097/00002281-200307000-00003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
354 Saraceno R, Saggini A, Pietroleonardo L, Chimenti S. Infliximab in the treatment of plaque type psoriasis. Clin Cosmet Investig Dermatol 2009;2:27-37. [PMID: 21436966 DOI: 10.2147/ccid.s3413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
355 Antoniou C, Stefanaki I, Stratigos A, Moustou E, Vergou T, Stavropoulos P, Avgerinou G, Rigopoulos D, Katsambas A. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre: Clinic’s experience with infliximab. British Journal of Dermatology 2010;162:1117-23. [DOI: 10.1111/j.1365-2133.2009.09578.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
356 Edwards CK, Bendele AM, Reznikov LI, Fantuzzi G, Chlipala ES, Li L, Moldawer LL, Mountz JD, Li YY, Dinarello CA. Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor α. Arthritis Rheum 2006;54:2872-85. [DOI: 10.1002/art.22077] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
357 Krygier DS, Ko HH, Bressler B. How to manage difficult Crohn's disease: optimum delivery of anti-TNFs. Expert Rev Gastroenterol Hepatol 2009;3:407-15. [PMID: 19673627 DOI: 10.1586/egh.09.25] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
358 Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut. 1997;40:443-448. [PMID: 9176068 DOI: 10.1136/gut.40.4.443] [Cited by in Crossref: 361] [Cited by in F6Publishing: 347] [Article Influence: 14.4] [Reference Citation Analysis]
359 Akobeng A, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd003574] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
360 Lin Z, Bai Y, Zheng P. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease. Eur J Gastroenterol Hepatol. 2011;23:1100-1110. [PMID: 21971373 DOI: 10.1097/MEG.0b013e32834b9544] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
361 Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther 2007;9 Suppl 1:S7. [PMID: 17634146 DOI: 10.1186/ar2171] [Cited by in Crossref: 97] [Cited by in F6Publishing: 81] [Article Influence: 6.5] [Reference Citation Analysis]
362 Nikolaus S, Raedler A, Kühbacker T, Sfikas N, Fölsch UR, Schreiber S. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000;356:1475-9. [PMID: 11081530 DOI: 10.1016/s0140-6736(00)02871-3] [Cited by in Crossref: 94] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
363 Monteleone G, Caprioli F. T-cell-directed therapies in inflammatory bowel diseases. Clin Sci (Lond). 2010;118:707-715. [PMID: 20350293 DOI: 10.1042/cs20100027] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
364 Lim KJ, Lee SJ, Kim S, Lee SY, Lee MS, Park YA, Choi EJ, Lee EB, Jun HK, Cho JM. Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease. J Crohns Colitis. 2017;11:593-602. [PMID: 28453766 DOI: 10.1093/ecco-jcc/jjw183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
365 Kawalec P, Mikrut A, Łopuch S. Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis: Biological therapy for ulcerative colitis. J Gastroenterol Hepatol 2014;29:1159-70. [DOI: 10.1111/jgh.12563] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
366 Yamane T, Yamamura R, Aoyama Y, Nakamae H, Hasegawa T, Sakamoto C, Shibata H, Terada Y, Koh G, Hino M. Infliximab for the Treatment of Severe Steroid Refractory Acute Graft-versus-host Disease in Three Patients after Allogeneic Hematopoietic Transplantation. Leukemia & Lymphoma 2011;44:2095-7. [DOI: 10.1080/1042819031000123483] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
367 Milman N, Andersen CB, Baslund B, Loft A, Iversen M. Does tumour necrosis factor-alpha inhibitor infliximab induce histological resolution of pulmonary sarcoid granulomas? Clin Respir J 2007;1:106-13. [PMID: 20298289 DOI: 10.1111/j.1752-699X.2007.00023.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
368 Malviya G, Conti F, Chianelli M, Scopinaro F, Dierckx RA, Signore A. Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies. Eur J Nucl Med Mol Imaging 2010;37:386-98. [PMID: 19777175 DOI: 10.1007/s00259-009-1272-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
369 Puthoor PR, de Zoeten EF. Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther. 2013;3:1-14. [PMID: 24392300 DOI: 10.1007/s13554-012-0006-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
370 Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for Refractory Ocular Sarcoidosis. Chest 2005;128:1062-7. [DOI: 10.1016/s0012-3692(15)50471-6] [Cited by in Crossref: 97] [Article Influence: 5.7] [Reference Citation Analysis]
371 Rosen HR, Lentz JJ, Rose SL, Rabkin J, Corless CL, Taylor K, Chou S. Donor polymorphism of tumor necrosis factor gene: relationship with variable severity of hepatitis C recurrence after liver transplantation. Transplantation. 1999;68:1898-1902. [PMID: 10628771 DOI: 10.1097/00007890-199912270-00014] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
372 Waetzig GH, Schreiber S. Mechanisms of infliximab: the reverse side of a drug effect. Inflamm Bowel Dis 2004;10 Suppl 1:S38-43. [PMID: 15168830 DOI: 10.1097/00054725-200402001-00009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
373 Holtmann MH, Neurath MF. From immunogenic mechanisms to novel therapeutic approaches in inflammatory bowel disease. Adv Exp Med Biol 2006;579:227-42. [PMID: 16620022 DOI: 10.1007/0-387-33778-4_15] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
374 Kallwellis-Opara A, Dörner A, Poller WC, Noutsias M, Kühl U, Schultheiss HP, Pauschinger M. Autoimmunological features in inflammatory cardiomyopathy. Clin Res Cardiol 2007;96:469-80. [PMID: 17503113 DOI: 10.1007/s00392-007-0524-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
375 Rosales Santillan M, Morss PC, Porter ML, Kimball AB. Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther 2020;20:621-33. [PMID: 32077334 DOI: 10.1080/14712598.2020.1732918] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
376 Alho HS, Maasilta PK, Harjula ALJ, Hämmäinen P, Salminen J, Salminen U. Tumor necrosis factor-α in a porcine bronchial model of obliterative bronchiolitis1. Transplantation 2003;76:516-23. [DOI: 10.1097/01.tp.0000074700.30536.76] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
377 Braun J, Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin Biol Ther 2003;3:141-68. [PMID: 12718738 DOI: 10.1517/14712598.3.1.141] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
378 Marino S, Sud D, Plessner H, Lin PL, Chan J, Flynn JL, Kirschner DE. Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue. PLoS Comput Biol 2007;3:1909-24. [PMID: 17953477 DOI: 10.1371/journal.pcbi.0030194] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
379 González-Gay MA, Agudo M. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies]. Med Clin (Barc) 2010;134:684-5. [PMID: 20176386 DOI: 10.1016/j.medcli.2009.12.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
380 Sands BE. Biologic Therapy for Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 1997;3:95-113. [DOI: 10.1097/00054725-199706000-00005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
381 Sandborn WJ. Transcending conventional therapies: The role of biologic and other novel therapies. Inflamm Bowel Dis 2001;7:S9-S16. [DOI: 10.1002/ibd.3780070504] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
382 Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease. Inflamm Bowel Dis 2012;18:1480-7. [PMID: 21987418 DOI: 10.1002/ibd.21886] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
383 Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55. [PMID: 12614731 DOI: 10.1016/s1473-3099(03)00545-0] [Cited by in Crossref: 492] [Cited by in F6Publishing: 130] [Article Influence: 25.9] [Reference Citation Analysis]
384 Attwood MM, Jonsson J, Rask-Andersen M, Schiöth HB. Soluble ligands as drug targets. Nat Rev Drug Discov 2020;19:695-710. [PMID: 32873970 DOI: 10.1038/s41573-020-0078-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
385 Hsia EC, Ruley KM, Rahman MU. Infliximab (RemicadeR): from bench to clinical practice. A paradigm shift in rheumatology practice. APLAR J Rheumatol 2006;9:107-18. [DOI: 10.1111/j.1479-8077.2006.00185.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
386 Agnholt J, Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 2001;15:212-22. [PMID: 11563881 DOI: 10.1006/cyto.2001.0919] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 2.9] [Reference Citation Analysis]
387 Baert FJ, D’Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology. 1999;116:22-28. [PMID: 9869598 DOI: 10.1016/s0016-5085(99)70224-6] [Cited by in Crossref: 326] [Cited by in F6Publishing: 99] [Article Influence: 14.2] [Reference Citation Analysis]
388 Olesen CM, Coskun M, Peyrin-Biroulet L, Nielsen OH. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacol Ther. 2016;159:110-119. [PMID: 26808166 DOI: 10.1016/j.pharmthera.2016.01.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 10.3] [Reference Citation Analysis]
389 Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301:418-426. [PMID: 11961039 DOI: 10.1124/jpet.301.2.418] [Cited by in Crossref: 458] [Cited by in F6Publishing: 424] [Article Influence: 22.9] [Reference Citation Analysis]
390 Vincek V, Jacob SE, Nassiri M, Herbert LM, Nadji M, Kerdel FA. Infliximab monotherapy in psoriasis: A case of rapid clinical and histological response. Int J Dermatol 2004;43:303-8. [DOI: 10.1111/j.1365-4632.2004.01961.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
391 Wang Y, Lin Q, Lin J, Du G, Matucci-Cerinic M. Infliximab Precipitated Urachal Remnant Infection. J Clin Rheumatol 2021;27:e219-21. [PMID: 30585998 DOI: 10.1097/RHU.0000000000000946] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
392 Akobeng AK. Infliximab for induction and maintenance theraphy for Ulcerative Colitis: . Journal of Pediatric Gastroenterology and Nutrition 2006;42:589-90. [DOI: 10.1097/01.mpg.0000221896.45910.9a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
393 Hori M, Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res 2009;81:457-64. [PMID: 19047340 DOI: 10.1093/cvr/cvn335] [Cited by in Crossref: 277] [Cited by in F6Publishing: 276] [Article Influence: 19.8] [Reference Citation Analysis]
394 Morales-lara MJ, Cañete JD, Torres-moreno D, Hernández MV, Pedrero F, Celis R, García-simón MS, Conesa-zamora P. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 2012;79:591-6. [DOI: 10.1016/j.jbspin.2012.02.003] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
395 Sands BE, Podolsky DK. New life in a sleeper: Thalidomide and Crohn's disease. Gastroenterology 1999;117:1485-8. [DOI: 10.1016/s0016-5085(99)70299-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
396 Meijer MJ, Mieremet-Ooms MA, van Duijn W, van der Zon AM, Hanemaaijer R, Verheijen JH, van Hogezand RA, Lamers CB, Verspaget HW. Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:200-210. [PMID: 17206679 DOI: 10.1002/ibd.20051] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 3.0] [Reference Citation Analysis]
397 Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, Gjertson D, Braun J, Reed E, Singh RR. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;126:121-136. [PMID: 17916444 DOI: 10.1016/j.clim.2007.08.013] [Cited by in Crossref: 182] [Cited by in F6Publishing: 182] [Article Influence: 12.1] [Reference Citation Analysis]
398 Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008;83:181-194. [PMID: 18241628 DOI: 10.1016/s0025-6196(11)60839-2] [Cited by in Crossref: 196] [Cited by in F6Publishing: 2] [Article Influence: 14.0] [Reference Citation Analysis]
399 Bell S, Kamm MA. Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease. Lancet 2000;355:858-60. [PMID: 10752696 DOI: 10.1016/S0140-6736(99)00442-0] [Cited by in Crossref: 69] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
400 Ch’en PF, Xu X, Liu X, Liu Y, Song C, Screaton GR, Jin B, Xu X. Characterisation of monoclonal antibodies to the TNF and TNF receptor families. Cellular Immunology 2005;236:78-85. [DOI: 10.1016/j.cellimm.2005.08.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
401 Olivas-Flores EM, Bonilla-Lara D, Gamez-Nava JI, Rocha-Muñoz AD, Gonzalez-Lopez L. Interstitial lung disease in rheumatoid arthritis: Current concepts in pathogenesis, diagnosis and therapeutics. World J Rheumatol 2015; 5(1): 1-22 [DOI: 10.5499/wjr.v5.i1.1] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
402 Vergou T, Moustou A, Sfikakis PP, Antoniou C, Stratigos AJ. Pharmacodynamics of TNF-α inhibitors in psoriasis. Expert Review of Clinical Pharmacology 2014;4:515-23. [DOI: 10.1586/ecp.11.28] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
403 Wang J, Anders RA, Wang Y, Turner JR, Abraham C, Pfeffer K, Fu Y. The Critical Role of LIGHT in Promoting Intestinal Inflammation and Crohn’s Disease. J Immunol 2005;174:8173-82. [DOI: 10.4049/jimmunol.174.12.8173] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 3.8] [Reference Citation Analysis]
404 Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D. Fcγ receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor α-blocking agents. Arthritis Rheum 2005;52:2693-6. [DOI: 10.1002/art.21266] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 5.0] [Reference Citation Analysis]
405 Moreland LW. Drugs that block tumour necrosis factor: Experience in patients with rheumatoid arthritis. Pharmacoeconomic 2004;22:39-53. [DOI: 10.2165/00019053-200422001-00005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
406 Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 2010;49:1215-28. [PMID: 20194223 DOI: 10.1093/rheumatology/keq031] [Cited by in Crossref: 392] [Cited by in F6Publishing: 365] [Article Influence: 32.7] [Reference Citation Analysis]
407 Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN, Braun MM. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565-2570. [PMID: 12384912 DOI: 10.1002/art.10583] [Cited by in Crossref: 330] [Cited by in F6Publishing: 278] [Article Influence: 16.5] [Reference Citation Analysis]
408 Murata Y, Olmarker K, Takahashi I, Takahashi K, Rydevik B. Effects of selective tumor necrosis factor-alpha inhibition to pain-behavioral changes caused by nucleus pulposus-induced damage to the spinal nerve in rats. Neurosci Lett 2005;382:148-52. [PMID: 15911139 DOI: 10.1016/j.neulet.2005.03.012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
409 Campanati A, Paolinelli M, Diotallevi F, Martina E, Molinelli E, Offidani A. Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis. Expert Opin Drug Metab Toxicol 2019;15:913-25. [PMID: 31623470 DOI: 10.1080/17425255.2019.1681969] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
410 Ebert EC. Infliximab and the TNF-α system. American Journal of Physiology-Gastrointestinal and Liver Physiology 2009;296:G612-20. [DOI: 10.1152/ajpgi.90576.2008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
411 Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, Robinson M, Bourne T. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13:1323-1332. [PMID: 17636564 DOI: 10.1002/ibd.20225] [Cited by in Crossref: 320] [Cited by in F6Publishing: 287] [Article Influence: 22.9] [Reference Citation Analysis]
412 Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-Hawes K, Armuzzi A, Crawshaw J, Fortune F, Walton R, Stanford MR, Welsh KI, Marshall SE, Jewell DP. Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum 2003;48:807-13. [PMID: 12632436 DOI: 10.1002/art.10815] [Cited by in Crossref: 101] [Cited by in F6Publishing: 84] [Article Influence: 5.3] [Reference Citation Analysis]
413 Barry RJ, Nguyen QD, Lee RW, Murray PI, Denniston AK. Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol 2014;8:1891-911. [PMID: 25284976 DOI: 10.2147/OPTH.S47778] [Cited by in Crossref: 4] [Cited by in F6Publishing: 22] [Article Influence: 0.5] [Reference Citation Analysis]
414 Cantini F, Nannini C, Niccoli L. Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Open Access Rheumatol 2009;1:163-78. [PMID: 27789989 DOI: 10.2147/oarrr.s4490] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
415 Liang S, Dai J, Hou S, Su L, Zhang D, Guo H, Hu S, Wang H, Rao Z, Guo Y, Lou Z. Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab. J Biol Chem 2013;288:13799-807. [PMID: 23504311 DOI: 10.1074/jbc.M112.433961] [Cited by in F6Publishing: 30] [Reference Citation Analysis]
416 Gulli S, Arrigo C, Bocchino L, Morgante L, Sangari D, Castagna I, Bagnato GF. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord 2003;4:19. [PMID: 12946278 DOI: 10.1186/1471-2474-4-19] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
417 Mascheretti S, Schreiber S. The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease. Pharmacogenomics 2004;5:479-86. [PMID: 15212584 DOI: 10.1517/14622416.5.5.479] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
418 Masuda H, Kobayashi T, Hachiya A, Nakashima Y, Shimizu H, Nozawa T, Ogihara Y, Ito S, Takatsuki S, Katsumata N, Suzuki Y, Takenaka S, Hirono K, Kobayashi T, Suzuki H, Suganuma E, Takahashi K, Saji T; Committee of Survey on Infliximab use for Kawasaki disease. Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan. J Pediatr 2018;195:115-120.e3. [PMID: 29224935 DOI: 10.1016/j.jpeds.2017.10.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
419 Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 2013;14:75-101. [DOI: 10.1517/14712598.2014.858695] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 9.4] [Reference Citation Analysis]
420 van der Woude CJ, Hommes DW. Biologics in Crohn's disease: searching indicators for outcome. Expert Opin Biol Ther. 2007;7:1233-1243. [PMID: 17696821 DOI: 10.1517/14712598.7.8.1233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
421 Eng GP, Bouchelouche P, Bartels EM, Bliddal H, Bendtzen K, Stoltenberg M. Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study. PLoS One 2016;11:e0162316. [PMID: 27606615 DOI: 10.1371/journal.pone.0162316] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
422 Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of etanercept and infliximab. Seminars in Arthritis and Rheumatism 2005;34:34-8. [DOI: 10.1016/j.semarthrit.2005.01.009] [Cited by in Crossref: 101] [Cited by in F6Publishing: 81] [Article Influence: 5.9] [Reference Citation Analysis]
423 Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2004;:CD003574. [PMID: 14974022 DOI: 10.1002/14651858.CD003574.pub2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 36] [Article Influence: 1.3] [Reference Citation Analysis]
424 Morelli J, Wilson FA. Does administration of infliximab increase susceptibility to listeriosis? Am J Gastroenterol. 2000;95:841-842. [PMID: 10710107 DOI: 10.1111/j.1572-0241.2000.01872.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 2.0] [Reference Citation Analysis]
425 Upton R, Bell L, Guy C, Caldwell P, Estdale S, Barran PE, Firth D. Orthogonal Assessment of Biotherapeutic Glycosylation: A Case Study Correlating N-Glycan Core Afucosylation of Herceptin with Mechanism of Action. Anal Chem 2016;88:10259-65. [PMID: 27620140 DOI: 10.1021/acs.analchem.6b02994] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
426 Chiu WC, Lai YP, Chou MY. Humanization and characterization of an anti-human TNF-α murine monoclonal antibody. PLoS One 2011;6:e16373. [PMID: 21305012 DOI: 10.1371/journal.pone.0016373] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
427 Louis E, El Ghoul Z, Vermeire S, Dall’Ozzo S, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Colombel JF. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn’s disease. Aliment Pharmacol Ther. 2004;19:511-519. [PMID: 14987319 DOI: 10.1111/j.1365-2036.2004.01871.x] [Cited by in Crossref: 159] [Cited by in F6Publishing: 138] [Article Influence: 8.8] [Reference Citation Analysis]
428 Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK. Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol. 2004;13:193-222. [PMID: 15086336 DOI: 10.1111/j.0906-6705.2004.00205.x] [Cited by in Crossref: 124] [Cited by in F6Publishing: 110] [Article Influence: 6.9] [Reference Citation Analysis]
429 Sands BE. Biologic therapy for inflammatory bowel disease. Inflamm Bowel Dis 1997;3:95-113. [DOI: 10.1002/ibd.3780030206] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
430 Noguchi M, Hiwatashi N, Liu Z, Toyota T. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut 1998;43:203-9. [PMID: 10189845 DOI: 10.1136/gut.43.2.203] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 3.3] [Reference Citation Analysis]
431 Machold KP, Smolen JS. Adalimumab – a new TNF-α antibody for treatment of inflammatory joint disease. Expert Opinion on Biological Therapy 2005;3:351-60. [DOI: 10.1517/14712598.3.2.351] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
432 Lopes JV, Freitas LAMD, Marques RD, Bocca AL, Sousa JBD, Oliveira PGD. Analysis of the tensile strength on the healing of the abdominal wall of rats treated with infliximab. Acta Cir Bras 2008;23:441-6. [DOI: 10.1590/s0102-86502008000500009] [Cited by in Crossref: 9] [Article Influence: 0.6] [Reference Citation Analysis]
433 Sandborn WJ. Strategies for targeting tumour necrosis factor in IBD. Best Practice & Research Clinical Gastroenterology 2003;17:105-17. [DOI: 10.1053/bega.2002.0345] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 3.2] [Reference Citation Analysis]
434 Yanagida M, Jung G, Tanaka Y, Sone S, Fujishiro M, Ikeda K, Nozawa K, Kaneko H, Takasaki Y, Ogawa H, Takamori K, Sekigawa I. Serum proteome analysis in patients with rheumatoid arthritis receiving therapy with etanercept, a chimeric tumor necrosis factor-alpha receptor. Int J Rheum Dis 2012;15:486-95. [PMID: 23083039 DOI: 10.1111/j.1756-185X.2012.01816.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
435 Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK. Alterations in the function of circulating mononuclear cells derived from patients with Crohn's disease treated with mastic. World J Gastroenterol 2007;13:6031-6. [PMID: 18023095 DOI: 10.3748/wjg.v13.45.6031] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
436 Mikuls TR, Weaver AL. Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Curr Rheumatol Rep 2003;5:270-7. [DOI: 10.1007/s11926-003-0005-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
437 Crum NF, Lederman ER, Wallace MR. Infections Associated With Tumor Necrosis Factor-α Antagonists. Medicine 2005;84:291-302. [DOI: 10.1097/01.md.0000180044.19285.9a] [Cited by in Crossref: 141] [Cited by in F6Publishing: 95] [Article Influence: 8.3] [Reference Citation Analysis]
438 Lopetuso LR, Petito V, Cufino V, Arena V, Stigliano E, Gerardi V, Gaetani E, Poscia A, Amato A, Cammarota G, Papa A, Sgambato A, Gasbarrini A, Scaldaferri F. Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice. Dig Liver Dis. 2013;45:1017-1021. [PMID: 23911613 DOI: 10.1016/j.dld.2013.06.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
439 Pascher A, Klupp J. Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFalpha inhibitors? BioDrugs 2005;19:211-31. [PMID: 16128605 DOI: 10.2165/00063030-200519040-00002] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 3.3] [Reference Citation Analysis]
440 Mössner R, Reich K. Infliximab in the treatment of psoriasis. Expert Review of Dermatology 2014;1:515-26. [DOI: 10.1586/17469872.1.4.515] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
441 Bewtra M, Lichtenstein GR. Infliximab use in Crohn’s disease. Expert Opinion on Biological Therapy 2005;5:589-99. [DOI: 10.1517/14712598.5.4.589] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
442 Leso V, Leggio L, Armuzzi A, Gasbarrini G, Gasbarrini A, Addolorato G. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update: . European Journal of Gastroenterology & Hepatology 2010;22:779-86. [DOI: 10.1097/meg.0b013e328331b654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
443 Ovejero-benito MC, Muñoz-aceituno E, Reolid A, Saiz-rodríguez M, Abad-santos F, Daudén E. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis. Am J Clin Dermatol 2018;19:209-22. [DOI: 10.1007/s40257-017-0322-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
444 Magro F, Rodrigues-Pinto E, Santos-Antunes J, Vilas-Boas F, Lopes S, Nunes A, Camila-Dias C, Macedo G. High C-reactive protein in Crohn’s disease patients predicts nonresponse to infliximab treatment. J Crohns Colitis. 2014;8:129-136. [PMID: 23932786 DOI: 10.1016/j.crohns.2013.07.005] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 5.3] [Reference Citation Analysis]
445 Carpenter PA, Sanders JE. Steroid-refractory graft-vs.-host disease: past, present and future. Pediatr Transplant 2003;7 Suppl 3:19-31. [PMID: 12603689 DOI: 10.1034/j.1399-3046.7.s3.3.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
446 Kawalec P, Pilc A. An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis. Arch Med Sci 2016;12:1097-109. [PMID: 27695502 DOI: 10.5114/aoms.2016.58682] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
447 Shen EH, Das KM. Current therapeutic recommendations: infliximab for ulcerative colitis. J Clin Gastroenterol 2004;38:741-5. [PMID: 15365397 DOI: 10.1097/01.mcg.0000140188.88275.65] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]